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Summary 
Information on genotoxicity is of a key importance for the toxicological characterisation of 
different compounds. In this vein, and due to its various advantages, the comet assay is 
currently included in the genotoxicity testing strategy used in the food safety area. However, 
improvement points of particular interest have been identified. Thereby, the main objective of 
the present work was to evaluate some critical points of the comet assay, such as the time of 
lysis, in vitro, and the methodology used in the freezing/thawing procedures of tissue samples, 
their stability and the application of the Fpg-modified assay, in vivo. In addition, the in vivo 
comet assay was applied to frozen kidney samples obtained in a previous repeated-dose 
toxicity study of the food contaminant ochratoxin A. Finally, the knowledge derived from these 
objectives resulted in the development of standard operating procedures for both the in vitro 
and in vivo comet assays, which could be applied in good laboratory practice studies.  
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1. DNA damage and mutagenicity 
DNA damage is defined as an alteration in the chemical structure of DNA, which occurs 
spontaneously, either as a result of the natural ageing process of cells (i.e., by endogenous 
agents), or as a consequence of the interaction with exogenous agents (i.e., xenobiotics). 
Therefore, DNA is not as stable as we tend to think, as a wide variety of both endogenous and 
exogenous agents can induce various kinds of DNA damage, such as single and double strand 
breaks (SSBs and DSBs, respectively), oxidised and alkylated bases, bulky adducts, intra- and 
inter-strand cross-links, adducts on the phosphodiester backbone and protein-DNA cross-links 
(see Figure 1).  
When a xenobiotic compound has the ability to damage DNA, it is considered genotoxic. 
Thereby, the term genotoxicity refers to the property of chemical agents to damage genetic 
information (DNA) and/or other cellular components which regulate the fidelity of the 
genome. 
 
Figure 1. Schematic diagrams of different DNA lesions. Adapted from Azqueta and Collins, 
2011. 
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DNA damage can have disruptive effects on transcription, DNA replication and chromosome 
segregation. A high level of DNA damage tends to trigger apoptosis, while lower levels are 
dealt with by effective DNA repair pathways. However, some DNA damage may remain 
unrepaired (or be misrepaired) when the cell replicates DNA, providing the basis for mutations, 
that are defined as stable changes in DNA sequence that can be transmitted to the offspring.  
As one may notice, genotoxicity and mutagenicity are pretty closed terms. As defined in the 
European Food Safety Authority (EFSA) Scientific opinion on genotoxicity testing strategies 
applicable to food and feed safety assessment (EFSA, 2011), “mutagenicity refers to the 
induction of permanent transmissible changes in the amount or structure of the genetic 
material of cells or organisms”. Traditionally, these changes are classified as gene mutations, 
which involve a single gene, or as chromosome mutations, involving a block of genes or 
chromosomes. More specifically, gene mutations are caused by a single base pair substitution 
or a deletion or insertion of a few base pairs (frameshift mutations). On the other hand, 
chromosome mutations can be divided into structural chromosome aberrations, produced by 
agents capable of causing breaks in chromosomes that result in the loss or rearrangements of 
chromosome segments (i.e., a clastogens), and numerical chromosome aberrations, produced 
by agents giving rise to a change (gain or loss) in chromosome number in cells (i.e., an 
aneugen) (see Figure 2). 
 
Figure 2. Examples of gene mutation (A), structural chromosome (B) and numerical 
chromosome (C) aberrations. 
Thus, fixation of DNA damage results in mutagenic effects that are generally considered to be 
essential for heritable effects and in the multi-step process of malignancy (ICH, 2012). Genetic 
alterations (i.e., both germ-line and somatic mutations, such as base pair changes, 
insertions/deletions, short tandem repeat expansions, copy number variants, transposon-
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mediated mutations and chromosome mutations) have been found to be important in human 
disease. Mutations in germ cells can lead to spontaneous abortions, infertility or heritable 
damage to the offspring and possibly to the subsequent generations. For example, three 
“number 21” chromosomes or trisomy 21, a form of aneuploidy, is characteristic of the Down 
syndrome.  
Cancer is a disease of somatic cells which is strongly linked to the occurrence of mutations. 
Somatic mutations may cause cancer if they occur in proto-oncogenes, tumour suppressor 
genes and/or DNA damage response genes. In fact, their role in the causation of cancer has 
been reviewed on several occasions (Lengauer et al., 1998) and has been proven, among 
others, for retinoblastoma (Knudson, 1971), neuroblastoma and pheochromocytoma (Knudson 
and Strong, 1972), and colorectal cancer (Ma et al., 2017). 
While the contribution of somatic mutations in the development of a cancer is considered 
essential and has been thoroughly studied, their role in non-malignant diseases (e.g., 
neurofibromatosis 1 and 2, McCune-Albright disease, paroxysmal nocturnal hemoglobinuria, 
incontinentia pigmenti in males, and many others affecting the central nervous system, heart 
and kidney) has only been confirmed recently due to the advances in molecular genetics 
(Erickson, 2010, 2003). 
In summary, all mutagenic compounds are genotoxic, as it is assumed that a mutation is 
present because a DNA lesion occurred previously. Thus, DNA lesions are also called pre-
mutagenic lesions. However, it is important to note that DNA damage reflects a dynamic 
steady state, in which the input of damage is normally balanced by the output (i.e., DNA 
repair).  
2. European Food Safety Authority strategy for genotoxicity testing 
Information on genotoxicity is essential not only for the risk assessment of pharmaceutical 
drugs, agrochemicals or industrial chemicals, but also of natural and environmental 
contaminants occurring in food and feed. Many regulatory agencies and advisory bodies have 
made recommendations on genotoxicity testing strategies. In the field of pharmaceutical 
drugs, the International Council for Harmonisation (formerly the International Conference on 
Harmonisation) of Technical Requirements for Pharmaceuticals for Human Use (ICH) has 
developed guidance on genotoxicity testing and data interpretation for pharmaceuticals 
intended for human use (ICH, 2012). This document was approved in its final version in 2011, 
resulting from the fusion of two previous documents that were approved in 1995 and 1997. 
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More recently, in the field of food and feed, EFSA has provided a Scientific opinion on 
genotoxicity testing strategies applicable to food and feed safety assessment (EFSA, 2011) and 
a Guidance for submission for food additive evaluations (EFSA, 2012). 
EFSA is a European agency which was funded by the European Union under the General Food 
Law (Regulation 178/2002). It was set up in 2002 following a series of food crises in the late 
1990s, with the aim of providing scientific advice and communication on risks associated with 
the food chain. Their competence in the risk assessment process covers the areas of food and 
feed safety, nutrition, animal health and welfare, plant protection and plant health (EFSA, 
2017). 
As stated in the latest version of the Guidance for submission for food additive evaluations 
(EFSA, 2012), published on August 2012, and elaborated by the EFSA Panel on Food Additives 
and Nutrient Sources added to Food (ANS), genotoxicity testing for risk assessment of 
substances in food and feed is performed with the following aims: 
- to identify substances which could cause heritable damage in humans, 
- to predict potential genotoxic carcinogens in cases where carcinogenicity data are 
not available, and 
- to contribute to understanding of the mechanism of action of chemical 
carcinogens. 
The document encompasses the description of the data requirements for authorisation of a 
new food additive or a modification of an already authorised one, and a description of the risk 
assessment paradigm applied, which includes hazard identification, hazard characterisation, 
exposure assessment and risk characterisation. It is divided into five sections: chemistry and 
specifications, information on existing authorisations and evaluations, proposed uses and 
exposure assessment, toxicological studies and supplementary information. Focusing on the 
toxicological studies (toxicokinetics and toxicity) section, it is divided into the following five 
subjects: toxicokinetics (ADME), genotoxicity, toxicity testing (subchronic, chronic and 
carcinogenicity), reproductive and developmental toxicology and additional studies. General 
considerations are given, and a tier approach is proposed for each one of these aspects. 
Finally, a combined tiered approach consisting in 3 tiers (see Figure 3) was designed to 
evaluate toxicokinetics, genotoxicity, toxicity (including subchronic toxicity, chronic toxicity 
and carcinogenicity), and reproductive and developmental toxicity (i.e., the core areas). Tier 1 
was developed as a minimal dataset applicable to all compounds, while Tier 2 applies to 
compounds which are absorbed and/or demonstrate toxicity in a 90-day toxicity study or in 
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vitro genotoxicity in Tier 1 tests. Tier 3 testing should be performed on a case-by-case basis to 
elucidate specific endpoints needing further investigation of findings in Tier 2 tests. 
This approach takes also into account the 3-Rs (replacement, refinement and reduction) 
animal testing strategy. 
 
Figure 3. Tiered toxicity testing for food additives. From EFSA, 2012. 
Testing for genotoxicity is considered a key aspect to move from Tier 1 to Tier 2, and also from 
Tier 2 to Tier 3. In vitro genotoxicity tests are applied in Tier 1 whereas in vivo genotoxicity 
tests are used in Tier 2.  
As it is the main topic of the present work, special focus is given to the genotoxicity strategy 
proposed by EFSA , which is based on the Scientific opinion on genotoxicity testing strategies 
applicable to food and feed safety assessment (EFSA, 2011).  
The Scientific Committee recommends a step-wise approach for the generation and evaluation 
of data on genotoxic potential (see Figure 4), which allows to assess the different endpoints 
implicated in carcinogenesis and heritable diseases. All the assays indicated in the figure, 
except the in vivo COMET assay, are identified by the corresponding Organisation for Economic 
Co-operation and Development (OECD) Test Guideline. The OECD Guideline for the in vivo 
COMET assay (OECD, 2016a) was approved later than the EFSA Scientific Opinion, and for this 
reason, it is not specified in the EFSA’s figure. These documents will be explained in the next 
section. 
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Figure 4. Schematic representation of the genotoxicity testing strategy recommended by the 
EFSA Scientific Committee. From EFSA, 2011. For references: OECD TG 471 (OECD, 1997); 
OECD TG 487 (OECD, 2016b); OECD TG 474 (OECD, 2016c); OECD TG 488 (OECD, 2013). 
For initial screening of substances for genotoxic potential, the in vitro core test battery should 
be able to detect the three important genotoxic endpoints; that is to say: gene mutations, 
structural chromosome aberrations (i.e., clastogenicity) and numerical chromosome 
aberrations (i.e., aneuploidy).  The Scientific opinion proposes the bacterial reverse mutation 
assay, which covers gene mutations, and the in vitro micronucleus test, which covers the 
endpoints of structural and numerical chromosome aberrations. Both in vitro tests should be 
conducted with and without an appropriate metabolic activation system, and cytotoxicity 
needs to be controlled. Further mammalian cells in vitro tests are not included, since it has 
been shown to reduce specificity with no substantial gain of sensitivity (EFSA, 2011). 
After these two in vitro assays have been performed, there are three possibilities: 
a) If all in vitro endpoints are clearly negative, then it can be concluded with reasonable 
certainty that the substance has no genotoxic potential. However, the Scientific 
Committee noted that, in rare exceptions, a small number of substances that are 
negative in vitro have positive results in vivo. Therefore, proceeding to in vivo testing 
with negative in vitro results should be considered case-by-case. 
b) In the case of inconclusive, contradictory or equivocal in vitro results, further in vitro 
testing may clarify the genotoxic potential in vitro. 
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c) One or more positive in vitro tests require follow up by in vivo testing, which would 
allow to conclude on the genotoxic potential of the test substance. Several in vivo 
follow-up approaches are proposed in the document and are explained below. In vivo 
studies should be chosen in relation to the genotoxic endpoint(s) identified in vitro, as 
well as by knowledge of bioavailability, reactivity, metabolism and target organ 
specificity of the test substance. They should be performed in appropriate target 
organs or tissues, demonstrating that the agent reaches the tissue under investigation, 
and adopting a step-wise approach. If the first study is positive, no further test would 
be needed, and the test substance would be considered as an in vivo genotoxin; if it is 
negative, it can be concluded that the test substance is not an in vivo genotoxin. 
However, a second in vivo test on an alternative tissue might be necessary if it 
becomes apparent that the substance did not reach the target tissue in the first test. 
Also, an in vivo test on a second endpoint may be necessary if more than one in vitro 
test is positive.  
The Scientific opinion considers the following in vivo tests for follow-up of in vitro positives:  
- The in vivo mammalian erythrocyte micronucleus test (OECD, 2016c), or 
alternatively, the in vivo mammalian bone marrow chromosome aberration test 
(OECD, 2016d). Any of these assays is an appropriate follow-up for in vitro 
clastogens and aneugens.  
- A transgenic rodent somatic and germ cell gene mutation assays (OECD, 2013), 
that can detect point mutations and small deletions, would be appropriate to 
follow-up in vitro gene mutagens. 
- The in vivo comet assay (OECD, 2016a), considered a useful indicator test in terms 
of its sensitivity to substances which cause gene mutations and/or structural 
chromosome aberrations (i.e., gene mutagens and clastogens, but not aneugens), 
has the advantage of being virtually applicable to any target tissue. 
Both the transgenic rodent mutation assay and the in vivo comet assay would be suitable as a 
follow-up for in vitro gene mutation positives, and for detecting first site of contact effects. 
However, the Scientific opinion clarifies that, while the first one measures gene mutations 
directly, the comet assay is an indicator test for DNA lesions that may or may not result in 
mutations. 
Finally, the Scientific Committee concluded that routine testing for genotoxicity in germ cells is 
not necessary, and it also recommends a documented weight-of-evidence approach to the 
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evaluation and interpretation of genotoxicity data, which takes into account other relevant 
data such as physico-chemical characteristics, structure-activity relationships, ADME, and the 
outcomes of any repeated-dose toxicity and carcinogenicity studies. 
Historically, the genetic toxicology testing battery has been designed to be used as a surrogate 
for carcinogenicity testing. However, clear evidence of genotoxicity in somatic cells in vivo 
must be considered an adverse effect per se, even if the results of cancer bioassays are 
negative, since genotoxicity is also implicated in other somatic diseases than cancer (see 
section 1). 
3. The OECD Guidelines for the Testing of Chemicals  
The OECD is an intergovernmental economic organisation, established in 1948 as the 
Organisation for European Economic Cooperation (OEEC) to run the US-financed Marshall Plan 
for reconstruction after World War II. In general terms, the mission of the Organisation is to 
promote policies designed to improve the economic and social well-being of people around 
the world. Among many other things, the Organisation sets international standards on a wide 
range of areas, from agriculture and tax to the safety of chemicals (OECD, 2017a).  
Each year, hundreds of new chemicals (i.e., industrial chemicals, pesticides, food additives, 
biotechnology products and pharmaceuticals) reach the market. The OECD assists countries in 
harmonising test methods for chemical safety and good laboratory practice. For this purpose, 
since 1981, OECD member and partner countries have been developing the OECD Guidelines 
for the Testing of Chemicals, a collection of the most relevant internationally agreed testing 
methods used by governments, industry and independent laboratories to assess the safety of 
chemical products, with the aim to (OECD, 2017b):   
- enhance the validity and international acceptance of test data; 
- make the best use of available resources in both governments and industry; 
- avoid the unnecessary use of laboratory animals; 
- minimise non-tariff trade barriers. 
In concrete terms, the OECD Test Guidelines (OECD, 2017b): 
• Cover safety testing of chemicals in its broadest sense, including physical-chemical 
properties and effects on different systems. 
• Are internationally accepted as standard methods for safety testing and provide the 
common basis for the Mutual Acceptance of Data, which implies the acceptance of the 
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data generated, in accordance with OECD Test Guidelines and Principles of Good 
Laboratory Practice (GLP), in other OECD countries and partner countries adhered to 
the Decision of the Council, avoiding duplicative testing. GLP sets the quality standards 
for the organisation and management of test facilities and for performing and 
reporting studies related to the safety of chemical substances and preparations. Thus, 
they help to ensure that studies submitted to regulatory authorities, to notify or 
register chemicals, are of sufficient quality and rigour and are verifiable. 
• Are essential for professionals working in industry, academia and government, and 
constitute a potent tool to be used not only in regulatory safety testing and in 
subsequent chemical product notification, registration and evaluation, but also in the 
selection and ranking of candidate chemicals during development, and in toxicology 
research, ensuring high-quality and reliable data. 
• Aim to reflect the current state-of-the-art in hazard identification and characterisation 
testing. For this purpose, these Guidelines are regularly updated with the assistance of 
thousands of national experts from OECD member countries. 
The OECD Guidelines for the Testing of Chemicals are divided into 5 sections: Physical-
Chemical Properties, Effects on Biotic Systems, Environmental Fate and Behaviour (formerly 
called Degradation and Accumulation), Health Effects, and Other Test Guidelines. Besides, 
there is a complete set of the series on OECD Principles of GLP. Within Section 4, Health 
Effects, the guidelines for both in vitro and in vivo genotoxicity assays can be found (OECD, 
2017c). Most of them have been recently revised. A summary of the genotoxicity assays 
included in the EFSA Scientific Opinion (EFSA, 2011) is presented in Table I. 
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Table I. In vitro and in vivo OECD Guidelines included in the EFSA Scientific opinion on 
genotoxicity testing strategies applicable to food and feed safety assessment (EFSA, 2011). 
OECD 
Guideline 
Title First adopted 
Last version 
adopted 
In vitro 
Test No. 471 Bacterial Reverse Mutation Assay 1983 1997 
Test No. 487 In Vitro Mammalian Cell Micronucleus Test 2010 2016 
In vivo 
Test No. 474 Mammalian Erythrocyte Micronucleus Test 1983 2016 
Test No. 475 
Mammalian Bone Marrow Chromosomal 
Aberration Test 
1984 2016 
Test No. 488 
Transgenic Rodent Somatic and Germ Cell 
Gene Mutation Assays 
2011 2013 
Test No. 489 In Vivo Mammalian Alkaline Comet Assay 2014 2016 
For references: Test No. 471 (OECD, 1997); Test No. 487 (OECD, 2016b); Test No. 474 (OECD, 
2016c); Test No. 475 (OECD, 2016d); Test No. 488 (OECD, 2013); Test No. 489 (OECD, 2016a). 
Basically, the structure of the OECD Guidelines is the same in all these cases. They contain a 
brief introduction, followed by initial considerations (and limitations) of the assay, a 
description of the verification of laboratory proficiency, the principle and description of the 
method sections, recommendations on the procedure, and finally, the data and reporting 
section. However, it should be noted that they provide minimum criteria for the acceptance of 
studies, and, therefore, additional requirements might be needed for each study (EFSA, 2012).       
4. The comet assay 
Östling and Johanson were the first to develop a microgel electrophoresis technique for 
detecting DNA damage at the level of the single cell in 1984 (Ostling and Johanson, 1984). 
However, it was not until 1988 that the most widely used protocol was described by increasing 
the alkalinity of the electrophoresis buffer to pH >13 (Singh et al., 1988). This technique is 
nowadays known as the single-cell gel electrophoresis assay or, more commonly, the comet 
assay. 
Under alkaline conditions (pH >13), the comet assay is able to detect single and double DNA 
strand breaks (SBs), as well as alkali-labile sites (ALS), notably the apurinic/apyrimidinic (AP) 
sites that are left when a base is lost from the DNA.  
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The scientific basis underlying the comet assay is relatively simple. Briefly, cells are 
immobilised in agarose on a support (a glass microscope slide or a plastic film) and lysed in a 
high salt solution that also contains detergent. This solution removes membranes, soluble 
cytoplasmic components and histones, to obtain nucleoids (i.e., DNA attached at intervals to 
the nuclear matrix as series of loops) (Cook et al., 1976). After an alkaline unwinding, DNA is 
denatured because of the disruption of hydrogen bonds between double-stranded DNA at pH 
values above 12.0 (Kohn, 1991). During this process, if strand breaks are present, the ultra-
structure of DNA as supercoiled loops is partially relaxed, thus being able to migrate towards 
the anode during electrophoresis. After staining with a suitable dye and visualising under the 
fluorescence microscope, the relative amount of DNA which has been able to migrate is 
quantified (usually as % tail DNA) by either manual, semi-automated or fully-automated 
scoring methods, reflecting the frequency of DNA SBs in each cell. The term ‘comet’ is 
therefore used to identify the individual cell DNA-migration patterns produced by this assay, 
which resemble stellar comets when visualised under the fluorescence microscope (Figure 5). 
Usually, about 100 comets are evaluated per cellular sample.  
 
Figure 5. Comet images of TK6 cells with different levels of DNA damage, from no damage in 
the left to medium and high damage. 
As mentioned before, the % tail DNA is the most commonly used parameter to describe a 
comet and so to describe a cellular sample by calculating the mean or the median of the % tail 
DNA of the evaluated comets. Another possibility is to express DNA damage in terms of actual 
DNA break frequency (e.g., ‘breaks per 106 base pairs’ or ‘breaks per cell’), which can be done 
by extrapolation of the % tail DNA from a calibration curve of cells exposed to ionising 
radiation (1 Gy of X- or ɣ-irradiation introduces 0.31 breaks per 109 Daltons of DNA; Ahnström 
and Erixon, 1981). 
The comet assay has several advantages in comparison with other genotoxicity assays, mainly 
the possibility to apply it to any cell suspension, including non-dividing cells and tissues from 
which a single cell/nuclei suspension can be obtained. Moreover, results are obtained at the 
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level of the single cell, thus providing information about the heterogeneity in sensitivity or 
response between cells, and a small number of cells is needed. Besides, the comet assay is a 
very sensitive technique which detects low levels of DNA damage (i.e., a few hundred DNA 
breaks per cell) (Tice et al., 2000).  
From a more practical point of view, the comet assay has also several advantages: it is a low-
cost assay, feasible to be incorporated in many laboratories since very specific equipment 
(apart from a fluorescence microscope) is not required, and a relatively short-time period is 
needed to complete an experiment.  
The comet assay has many different applications other than in vitro and in vivo genotoxicity 
testing. This technique is widely used in human biomonitoring and ecogenotoxicology and, 
during the last years, it has also been used in clinical applications at a research level. 
Moreover, it is also used in basic research into mechanisms of DNA damage and repair.  
4.1. Modifications of the comet assay  
As mentioned in the previous section, the standard version of the comet assay detects both 
DNA SBs and ALS. However, with some modifications, a wider scope of lesions can be 
detected.  
First of all, digestion of nucleoids with lesion-specific enzymes from the bacterial and human 
DNA repair machinery, allows the detection of altered (e.g., oxidised or alkylated) bases. These 
enzymes induce (additional) breaks in the sites of these altered bases which are easily 
measured following the rest of the assay’s protocol. Formamidopyrimidine-DNA glycosylase 
(Fpg), which detects a variety of DNA lesions including oxidised purines (Table II), is the most 
frequently used. Figure 6 shows a scheme of the standard comet assay protocol and the 
modified assay including digestion with lesion-specific enzymes (Fpg or Endocuclease III) to 
detect oxidised bases. Examples of different DNA repair enzymes which have been already 
used in combination with the comet assay are provided in Table II. The majority of them have 
been extensively used in the context of human biomonitoring (Azqueta and Collins, 2013).  
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Table II. Examples of human and bacterial DNA repair enzymes used in combination with the 
comet assay. 
Enzyme; Enzyme Commission 
(EC) Number 
Origin Type of lesion(s) detected Reference 
Endonuclease III (Endo III);     
EC 4.2.99.18 
Bacterial  Oxidised pyrimidines 
Collins et al., 
1993 
Formamidopyrimidine-DNA 
glycosylase (Fpg); EC 3.2.2.23 
Bacterial 
Oxidised purines (8-oxoGua*), 
ring-opened purines and       
ring-opened N7 guanine adducts 
Dusinska and 
Collins, 1996 
8-oxoguanine DNA glycosylase 
(OGG1); EC 4.2.99.18 
Human 8-oxoGua 
Smith et al., 
2006 
3-methyladenine glycosylase II 
(Alk A); EC 3.2.2.21 
Bacterial  3-methyladenine 
Berdal et al., 
1998 
Uracil DNA glycosylase (UDG); 
EC 3.2.2.3 
Human Misincorporated uracil 
Duthie and 
McMillan, 1997 
Pyrimidine dimer DNA 
glycosylase (T4     
endonuclease V); EC 3.1.25.1 
Bacterial 
UV-induced dimerised 
pyrimidines 
Collins et al., 
1997 
*8-oxo-7,8-dihydroguanine (8-oxoGua) 
Using the enzymes in combination with the comet assay seems to be a very useful tool in 
genotoxicity testing since other DNA lesions apart from SBs can be detected. However, their 
specificity has not been thoroughly studied in all the cases yet. For example, apart from 
detecting oxidative DNA damage, Fpg also attacks ring-opened N7 guanine adducts produced 
by alkylating agents (Li et al., 1997; Speit et al., 2004). Nevertheless, Azqueta et al. (2013a) 
proved that Fpg  enhanced the sensitivity of the in vitro alkaline comet assay in genotoxicity 
testing without losing its selectivity by testing 11 chemicals in TK6 cells.  
Other modifications of the comet assay allow the measurement of DNA-DNA cross-links (e.g., 
Spanswick et al., 2010), DNA-protein cross-links (e.g., Tice et al., 2000), DNA repair activity 
(reviewed in Azqueta et al., 2014) and even global methylation (Georgieva et al., 2017; Lewies 
et al., 2014; Wentzel et al., 2010). Moreover, the combination of the comet assay with 
fluorescent in situ hybridization (FISH) has been used to detect specific genes (reviewed in 
Shaposhnikov et al., 2009). It is worth to mention that all these modifications have been used 
in human biomonitoring or in basic research but their application in genotoxicity testing, if 
relevant, has not been explored.   
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Figure 6. Scheme of the standard comet assay (A), and the modified assay including digestion 
with lesion-specific enzymes to detect oxidised bases (B). From Azqueta and Collins, 2011. 
4.2. The dark side of the comet assay and some good news 
Scoring comets is a tedious task that implies a lot of hours at the microscope. Automated 
scoring methods have been developed by different companies (e.g., Imstar, Metasystems). 
They are very useful tools, under continuous improvements, though still not always very 
accurate in detecting and analysing all comets. In any case, the unaffordable prices of these 
systems make it almost impossible to use them at the research level.  
On the other hand, the efficiency of the traditional version of the assay, in which 1, 2 or 3 large 
gels are placed on a microscope slide, is rather low due to the limited number of samples that 
can be processed in one experiment (normally determined by the number of slides that can be 
placed on a conventional electrophoresis tank). However, several authors have developed 
their own medium and high-throughput methods (reviewed in Brunborg et al., 2014), some of 
which are very easy to implement (e.g., placing multiple mini-gels on top of microscope slides 
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or plastic GelBond® Films), and only slight modifications of the protocol are needed (Gutzkow 
et al., 2013; Mcnamee et al., 2000; Shaposhnikov et al., 2010). Validation of the medium- and 
high-throughput methods against the traditional version has been carried out by different 
authors, showing that similar results are obtained (Azqueta et al., 2013b). By applying these 
methods, the cost and time to process samples are reduced, but the number of samples to 
score increases substantially and thus the development of low-cost automated scoring systems 
is urgently required.  
From the earliest papers, it was noticed that the variability in the application of the technique 
itself consistently difficulted inter-laboratory comparison of results (Fairbairn et al., 1995); that 
is to say, differences in the protocols used by different research groups made it hard to 
compare results between laboratories. Relatively high inter-laboratory variation has been 
reported in various studies (ESCODD, 200; Ersson et al., 2013; Forchhammer et al., 2012, 2010; 
Johansson et al., 2010; Møller et al., 2010). Moreover, quite high inter-experimental variation 
(Azqueta and Collins, 2013 and Møller et al., 2010) as well as intra-assay variation has been 
also reported (Gutzkow et al., 2013 and Møller et al., 2010). As it is explained in the next 
section, a lot of effort has been done in order to reduce the variation of the comet assay.  
4.3. Standardisation of the assay 
An expert panel was convened at the International Workshop on Genotoxicity Test Procedures 
(IWGTP), held in in Washington in March 1999, in order to identify minimal standards for 
obtaining reproducible and reliable comet assay data deemed suitable for regulatory 
submission. They reached the consensus that the alkaline comet assay was optimal for 
identifying agents with genotoxic activity. In addition, the critical technical steps of both the in 
vitro and in vivo versions of the assay were discussed, and guidelines developed (Tice et al., 
2000). More detailed practical guidance to conduct the in vivo comet assay for regulatory 
purposes was published later (Hartmann et al., 2003a). 
Some important factors influencing the outcome of the comet assay have been thoroughly 
studied to date. Final agarose concentration in gels is inversely proportional to the levels of 
DNA damage detected in treated cells (Azqueta et al., 2011; Ersson and Möller, 2011). On the 
other hand, increasing the duration of the alkaline treatment (Azqueta et al., 2011; Ersson and 
Möller, 2011; Speit et al., 1999; Vijayalaxmi et al., 1992; Yendle et al., 1997) and 
electrophoresis (Azqueta et al., 2011; Ersson and Möller, 2011; Speit et al., 1999; Vijayalaxmi 
et al., 1992), as well as the voltage applied in the electrophoresis tank (Azqueta et al., 2011; 
Ersson and Möller, 2011), have shown to increase the extent of DNA damage measured.  
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Scoring is also considered a critical step. It has been demonstrated that different 
concentrations of dye also affect the assay’s sensitivity to detect DNA damage (Olive et al., 
1990). Besides, microscope quality and adjustments, aging of the UV lamp and settings within 
the image analysis software also affect the results.  
When using the Fpg-modified assay, both the duration of the alkaline and enzyme incubations 
has been shown to affect the detection of enzyme-sensitive sites (Ersson and Möller, 2011).  
Recently, general recommendations to carry out the comet assay taking into account those 
critical factors were published (Azqueta and Collins, 2013). Moreover, an OECD Guideline to 
carry out the in vivo comet assay was published in 2014 (OECD, 2016a) (see section 5.1.1). 
4.4. Reducing variability 
In an inter-laboratory study carried out by 14 participating laboratories, Ersson et al. (2013) 
assessed the inter- and intra-laboratory, sample and residual variations in DNA SBs and Fpg-
sensitive sites measured with the comet assay in coded peripheral blood mononuclear cells 
(PBMC); what they found was that inter-laboratory variation accounted for the largest fraction 
of the overall variation. Godschalk et al. (2014) came to the same conclusion in another inter-
laboratory-variation study involving 13 different laboratories. Though standardisation of the 
assay and the development of standard protocols are crucial for controlling data variation, 
adherence to a standard protocol only slightly reduced the inter-laboratory variation in Fpg-
sensitive sites detected in human mononuclear blood cells (MNBCs) (Forchhammer et al., 
2012). In addition, comet scoring does not entirely depend on the comet assay protocol 
applied; as it has been mentioned before, results depend on the microscope quality and 
adjustments, the aging of the UV lamp and the settings within the image analysis software.  
Inclusion of reference standards (i.e., cells with a known amount of specific DNA damage) or 
normalisation of results using a calibration curve (usually performed with X-ray-treated cells) 
have been proposed as valuable tools to reduce the inter-experimental variation (Azqueta and 
Collins, 2013; Collins et al., 2014; Zainol et al., 2009). Moreover, the latter approach led to a 
statistically significant reduction in the coefficient of variation (CV, from 47% to 28%) of the 
DNA damage obtained by 12 different laboratories in irradiated monocyte-derived THP-1 cells 
(Forchhammer et al., 2010). A similar approach was used to reduce the variation in the Fpg-
sensitive sites of X-irradiated A549 lung epithelial cells estimated by different investigators 
(Møller et al., 2004), in the oxidised purines detected in MNBCs exposed to ɣ-radiation 
(Forchhammer et al., 2008), and the inter-laboratory variation found between 10 laboratories 
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in the measurement of Fpg-sensitive sites, which was mainly due to protocol differences 
(Johansson et al., 2010). 
Last but not least, controlled electrophoresis (including circulation of the electrophoresis 
solution) has been shown to improve the homogeneity between replicate samples (i.e., intra-
assay variability) in a 96-mini-gel format (Gutzkow et al., 2013) and will probably reduce the 
inter-experimental variability.   
The European Standards Committee on Oxidative DNA Damage (ESCODD) sent photosensitiser 
plus light-treated HeLa cells to compare the levels of 8-oxoGua measured with the Fpg-
modified comet assay to 10 different laboratories (ESCODD, 2003). Among them, only 5 were 
able to detect a dose-response. In another study (Gedik and Collins, 2005), they found a 10-
fold variation in the Fpg-sensitive sites of control HeLa cells measured in 8 different 
laboratories (six of them followed the same protocol).   
Notwithstanding the identification of several critical assay parameters, and the numerous 
inter-laboratory trials carried out by the European Standards Committee on Oxidative DNA 
Damage (ESCODD, 2003; Gedik and Collins, 2005) and, primarily, by the European Comet Assay 
Validation Group (ECVAG; Ersson et al., 2013; Forchhammer et al., 2012, 2010; Godschalk et 
al., 2014; Johansson et al., 2010) to both assess the variability and try to control or even 
decrease it, further studies are needed as to definitely eliminate variability from the comet 
assay, notably the one added in the staining, scoring and image analysis steps (Collins et al., 
2014).  
5. The comet assay in regulatory (geno)toxicology 
Although the comet assay has been extensively used for almost 30 years now, its role in 
regulatory genotoxicology was rather limited. This might be probably due to the fact that the 
standard alkaline comet assay detects DNA SBs (and ALS), which are quickly repaired and not 
very relevant in terms of genetic stability. Moreover, other in vitro assays detecting gene 
mutations and structural and numerical chromosome aberrations were already available. In 
addition, the high inter-experimental and inter-laboratory variation did not play in its favour.  
However, a great advantage of the comet assay is that it can be applied to any organ as long as 
a cell suspension can be obtained, and in non-dividing cells; this characteristic makes it very 
useful in testing in vivo genotoxicity since the majority of the aforementioned assays are 
applied in blood or bone marrow cells (i.e., dividing cells). During the last years, both the in 
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vivo and the in vitro versions of the comet assay have made their way into regulatory 
toxicology. 
5.1. The in vivo comet assay  
5.1.1. OECD Guideline 
Already in 2004, the in vivo comet assay was suggested to be used as a complementary assay 
for mechanistic investigations following positive in vitro findings and to evaluate target organ-
specific genotoxicity for the critical risk assessment within the regulatory acceptance of 
pharmaceuticals (Hartmann et al., 2004). Guidelines and recommendations were published all 
over the world by scientific committees and regulatory agencies such as the Committee on 
Mutagenicity of Chemicals in Food, Consumer products and the Environment (COM), the U.S. 
Food and Drug Administration Centre for Drug Evaluation and Research (FDA-CDER) and the 
European Medicines Agency (EMA) (reviewed in Cimino, 2006). During the 4th International 
Comet Assay Workshop on Genotoxicity Testing (IWGT), held in San Francisco (California) in 
September 2005, some of the procedures and methods recommended to carry out the in vivo 
rodent alkaline comet assay were discussed in order to maximize its acceptance for regulatory 
purposes (Burlinson et al., 2007), while critical topics related to its use in regulatory 
genotoxicity testing were evaluated by an expert working group during the 6th IWGT, held in 
Foz do Iguacu (Brazil) in October/November 2013 (Speit et al., 2015). 
Although international agreed protocols were available, it was not until the first formal 
validation trial, coordinated by the Japanese Center for the Validation of Alternative Methods 
(JaCVAM), in conjunction with the U.S. NTP Interagency Center for the Evaluation of 
Alternative Toxicological Methods (NICEATM), the Interagency Coordinating Committee on the 
Validation of Alternative Methods (ICCVAM), the European Centre for the Validation of 
Alternative Methods (ECVAM), and the Japanese Environmental Mutagen Society/Mammalian 
Mutagenesis Study Group (JEMS/MMS) (Uno et al., 2015a, 2015b), that an In vivo Mammalian 
Alkaline Comet Assay OECD (TG 489) Guideline was achieved. The first version was approved in 
2014, while the last one was adopted on 29th July 2016 (OECD, 2016a). In line with the ‘three 
Rs’ (Reduce, Refine and Replace) principles, the Guideline considers the integration of the 
comet assay into repeated-dose toxicity studies, or its combination with other genotoxicity 
endpoints such as the micronucleus assay.   
The guideline establishes common laboratory strains of healthy young adult rodents (6-10 
weeks old) to be used. Regarding the experimental design, a minimum of 5 analysable animals 
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of one sex (or of both sexes if there is existing data demonstrating relevant sex-differences) 
should be used. For both acute and sub-acute versions of the comet assay, the maximum 
tolerated dose (MTD), together with a descending sequence of at least two additional 
appropriately spaced dose levels should be selected, covering a range from the maximum to 
little or no toxicity. For a non-toxic test chemical, the Guideline provides maximum (limit) 
doses depending on the administration period. Animals should be treated daily over 2 or more 
days, and samples should be collected once at 2-6 h after the last treatment in order not to 
miss transient DNA lesions. As no inter-laboratory studies have been conducted in tissues 
other than liver and stomach, no recommendations about optimum or acceptable ranges for 
other tissues are available (the group mean % tail DNA should not exceed 6% for rat liver). 
However, the Guideline mentions several other tissues to which the technique has been 
applied. For each sample, the Guideline establishes that 150 cells should be analysed at least, 
being the % tail DNA recommended for the interpretation of results. Regarding the 
interpretation of results, a test chemical is considered able to induce DNA strand breakage if 
the 3 following criteria are met: at least one of the test doses exhibits a statistically significant 
increase compared with the negative control, the increase is dose-related, and any of the 
results are outside the distribution of the historical negative control data for the given 
experimental conditions. However, it is emphasised that tissue cytotoxicity might result in an 
increased DNA migration, for which examination of histopathological changes is considered a 
relevant measure. Anyway, a careful interpretation of results should be done in the presence 
of clear signs of cytotoxicity. 
As a result of the final validation study, the comet assay was considered highly capable of 
identifying genotoxic chemicals (at least in liver and stomach, although other tissues could be 
used), and therefore could serve as a reliable predictor of rodent carcinogenicity (Uno et al., 
2015b). However, as inter-laboratory studies have been only carried out in liver and stomach, 
no recommendation has been established for how to achieve a sensitive and reproducible 
response in other tissues, such as expected positive and negative control ranges. In addition, 
the Guideline recognises the possibility of using frozen tissues, as long as the laboratory 
demonstrates its competency in freezing methodologies, confirms acceptable low ranges of % 
tail DNA in target tissues of vehicle treated animals and the detection of positive responses. 
Regarding the use of lesion-specific enzymes or other modifications of the assay to detect 
other types of DNA lesions, the Guideline states that further work would be needed to 
characterize the necessary protocol modifications.  
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Nowadays, the in vivo comet assay is part of the strategy suggested by the ICH (ICH, 2012) and 
it is also contemplated by the European Food Safety Authority for the genotoxicity testing of 
compounds in food and animal feedstuffs (EFSA, 2011) (see section 2). Overall, the number of 
applications containing in vivo comet assay data has increased since 2007, and this trend is 
expected to be sustained (Frötschl, 2015). 
5.1.2. Combination of the in vivo comet assay with other assays 
Already in 1991, it was raised that in vivo genotoxicity tests could be combined with other 
toxicological investigations (e.g., within the framework of 28-day tolerance studies) (Fahrig et 
al., 1991). During the 5th International Workshop on Genotoxicity Testing (IWGT), held in Basel 
(Switzerland) in August 2009, a working group discussed how to improve in vivo genotoxicity 
assessment, while, at the same time, trying to implement the ‘three Rs’ concept. Due to the 
low sensitivity of the liver unscheduled DNA synthesis (UDS) test in the detection of rodent 
carcinogens which were not detected with the in vivo micronucleus test (they both were 
traditionally used as in vivo follow-up tests), other methods were searched as possible 
replacements for that endpoint. In this context, the working group discussed and finally agreed 
that it was technically feasible and scientifically acceptable to combine and integrate the in 
vivo micronucleus and liver comet assays for both acute and repeated dose studies (Rothfuss 
et al., 2011, 2010). The technical feasibility and complementary use of different target organs 
and genetic endpoints, in addition to similar experimental requirements, strongly support the 
combination of these two assays.  
During the 6th IWGT (held in Brazil in 2013), it was corroborated that integration of the comet 
assay into a repeated-dose toxicity study, as well as the combination of the comet assay with 
an acute MN assay are possible (Speit et al., 2015), which had been already discussed as 
available and scientifically credible reduction options in the number of animals at the ECVAM 
workshop held in Italy in June 2008 (Pfuhler et al., 2009). In fact, the NTP uses the second 
approach to evaluate the genotoxicity of substances of public concern (Recio et al., 2010). 
Moreover, the ICH guidelines for genotoxicity testing (ICH, 2012) and the Integrated Testing 
Strategy (ITS) of the Registration, Evaluation, Authorisation and Restriction of Chemical 
Substances (REACH) programme of the European Commission (ECHA, 2017) also promote the 
integration of genotoxicity tests into repeated-dose toxicity studies. 
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5.1.3. The in vivo comet assay versus other genotoxicity assays 
Sasaki et al. (2000) found that 49 out of 54 rodent carcinogens that did not induce micronuclei 
were positive in the comet assay, suggesting that it could be used as a further in vivo test apart 
from the cytogenetic assays in hematopoietic cells. However, this paper has been criticised 
because it does not fully meet the requirements for an acceptable test agreed during the 
IWGTP meeting in Washington in 1999 (Tice et al., 2000). In the same vein, the ability of the in 
vivo UDS, transgenic mutation and comet assays to detect rodent carcinogens which gave 
either negative or equivocal results in the bone-marrow MN test has been compared (Kirkland 
and Speit, 2008). Among them, the comet assay was found to be the most sensitive test 
(almost 90% of the micronucleus-negative or equivocal carcinogens were detected), with an 
acceptable specificity (78% negative results with non-carcinogens). Finally, in a collaborative 
trial (Rothfuss et al., 2010), another group of experts reached the conclusion that the liver 
comet assay (using either a short- or a long-term protocol) was a reasonable alternative to the 
UDS test.  
5.2. The in vitro comet assay 
5.2.1. Validation of the in vitro comet assay 
In vitro genotoxicity tests in mammalian cells produce a remarkably high and unacceptable 
occurrence of irrelevant positive results; thus, better guidance on the likely mechanisms 
involved, and how to obtain evidence for those mechanisms, is needed (Kirkland et al., 2007). 
In fact, improving current in vitro tests in order to reduce false positives and to avoid 
unnecessary in vivo follow-up tests, present major challenges for genetic toxicologists (Pfuhler 
et al., 2011, 2009). 
However, it is known that a great part of the false positives reported by the comet assay, and 
by other in vitro genotoxicity assays, are caused by testing cytotoxic concentrations of the 
compounds (i.e., cell death causes secondary DNA that may lead to the incorrect positive 
classification of a chemical) (Fowler et al., 2012). In the in vitro comet assay, it is 
recommended to avoid concentrations of a test chemical producing high (>30%) mortality 
(Tice et al., 2000). In this context, cell proliferation assays are the best measures of cytotoxicity 
(Fowler et al., 2012; Kirkland, 2011). 
When evaluating the suitability of the comet assay as a screening test during industrial drug 
development, a high degree of concordance was found between the results of the in vitro 
comet assay and the in vitro MN test by analysing 36 pharmaceutical compounds with 
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unknown genotoxic potential (Hartmann et al., 2001). In another study, Hartmann et al. 
(2003b) found a high degree of agreement between the in vitro comet assay and the 
chromosome aberration test for 13 drug candidates. Furthermore, the sensitivity of the in vitro 
comet assay has been shown to be similar than the one of the micronucleus, chromosome 
aberration and sister chromatid exchange assays (Uhl et al., 1999). Nonetheless, the in vitro 
comet assay is not regarded as a standard battery test, and it is rarely submitted for regulatory 
purposes (Frötschl, 2015). 
Nowadays, the in vitro version of the alkaline comet assay is widely used for genotoxicity 
screening of novel cosmetics, nanomaterials and pharmaceuticals, and it is also recommended 
as an appropriate test for use under the REACH programme of the European Commission 
(ECHA, 2017). However, the initiative implemented by EURL-ECVAM to evaluate the validity of 
the in vitro comet assay (Burlinson et al., 2007) is currently stopped (EURL-ECVAM, 2014). 
5.2.2. The in vitro comet assay in 3D skin models 
The prohibition of animal testing for cosmetic ingredients as from March 2013 (Regulation 
1223/2009), together with the availability of in vitro models adequately reproducing human 
skin, position the in vitro comet assay as a good option in this area.  
During the 5th IWGT (Rothfuss et al., 2011), the results of a project sponsored by the former 
European Cosmetics Industry Association (COLIPA), with a contribution from ECVAM, were 
presented. In addition to the pre-validation studies of the in vitro reconstructed skin 
micronucleus (RSMN) assay, a good inter-laboratory reproducibility of the 3D skin comet assay 
was demonstrated for the direct-acting mutagens methyl methanesulfonate (MMS) and 4-
nitroquinoline 1-oxide using three different real skin models.  
Nowadays, the validation study, coordinated by Cosmetics Europe, in collaboration with the 
European Union Reference Laboratory for alternatives to animal testing (EURL-ECVAM), is still 
ongoing (EURL-ECVAM, 2014).   
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1. AIM 
It seems clear that both the in vivo and in vitro versions of the comet assay have a wide range 
of applications, and nobody ventures to discuss their usefulness. However, the trip for the 
standardisation of the assay has not been easy. Indeed, it is not yet completed.  
1.1. In vitro comet assay 
As mentioned in the introduction, several critical points affecting the outcome of the alkaline 
comet assay have been already identified. Lysis conditions are considered a critical variable 
that may interfere with the outcome resulting from specific types of DNA modifications 
(certain DNA alkylations and base adducts). Thereby, it is recommended to keep lysis 
conditions as constant as possible for all the slides within an experiment (from 1 hour to 
overnight lysis at around 2-8°C under subdued lighting conditions). However, the influence of 
lysis conditions (i.e., lysis duration and composition of the lysis solution) has not been 
thoroughly studied.  
1.2. In vivo comet assay 
Taking the “Initial considerations and limitations” section of the In vivo Mammalian Alkaline 
Comet Assay OECD (TG 489) Guideline as a reference, someone can easily detect improvement 
points of particular interest. 
The first one has to do with the tissues to which the comet assay can be applied. Although the 
Guideline recognises that the technique is in principle applicable to any tissue from which 
analysable single cell/nuclei suspensions can be derived, it encourages the laboratory to 
demonstrate proficiency with each individual tissue in each species they are planning to study, 
and that an acceptable positive response with a known mutagen can be obtained in that 
tissue. The group mean % tail DNA in the rat liver should not exceed 6%, although it does not 
give recommendations about acceptable ranges for other tissues. As inter-laboratory studies 
have been only carried out in liver and stomach, no recommendation has been established for 
how to achieve a sensitive and reproducible response in other tissues 
The second one concerns the chance to freeze tissues or cell nuclei for later analysis, which has 
been already successfully described, usually resulting in a measurable effect on the response 
to the vehicle and positive control. However, the Guideline suggests that, if used, the 
laboratory should demonstrate competency in freezing methodologies and confirm acceptable 
low ranges of % tail DNA in target tissues of vehicle treated animals, as well as being able to 
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detect positive responses. In addition, although the freezing of tissues has been described 
using different methods, currently there is no agreement on the best way to freeze and thaw 
tissues. 
In the same vein, another two questions come to mind: Is it possible to apply the Fpg-modified 
assay to frozen tissue samples? And, for how long can tissue samples be frozen for later comet 
analysis? With regard to the first one, this possibility is not even contemplated in the in vivo 
OECD Guideline; although it recognises that oxidised bases might be detected, the necessary 
protocol modifications are supposedly not still adequately characterised. With regard to the 
second one, according to our knowledge, there is no article specifically studying the long-term 
stability of frozen tissue samples, another key issue. 
2. Objectives and outline 
Therefore, the aim of the present project is to contribute to the standardisation of the in vitro 
and in vivo comet assays by providing knowledge of their critical points, and therefore to 
increase their applicability from a regulatory point of view. 
Objectives: 
1. To study the influence of the time of lysis and lysis solution composition in the in vitro 
alkaline comet assay results.   
For this purpose, two different approaches were used: 
1.1. Different times of lysis (from no lysis to 1 week) were tested in HeLa cells untreated or 
treated with compounds able to induce alkylated bases or oxidative DNA damage: 
methyl methanesulfonate (MMS), H2O2 or Ro 19-8022 + light (the Fpg-modified assay 
was used in the last case). Chapter 3. 
1.2. Different times of lysis (from no lysis to 1 week) and two different lysis solutions were 
tested in control and X-ray-treated TK6 cells, which mainly induces DNA single strand 
breaks. Chapter 4. 
2. To study the best freezing/thawing method for the tissue samples in order to apply the in 
vivo alkaline comet assay with/without Fpg. Chapter 5.  
For this purpose, a step-wise approach was followed: 
2.1. First of all, different freezing/thawing methods were tested in frozen liver tissue 
samples from untreated animals to select the best one. 
2.2. Secondly, the best method was used to compare the DNA damage detected in fresh 
and frozen (for different time-lengths) liver, kidney and lung tissue samples from rats 
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orally administered with different concentrations of MMS. Again, both the standard 
and the Fpg-modified comet assays were used. 
3. To apply the in vivo alkaline comet assay to frozen kidney tissue samples obtained in a 
previous repeated-dose toxicity study of the food contaminant ochratoxin A (OTA). For this 
purpose, samples from male and female F344 rats orally administered with different doses 
of OTA for 7 or 21 days were analysed. Furthermore, oxidative DNA damage was 
phenotypically collated by determining glutathione S-transferase (GST) activity, total 
(tGSH) and oxidised (GSSG) glutathione levels and superoxide dismutase (SOD) activity in 
kidney tissue samples from the same animals. Chapter 6. 
4. To collaborate in the elaboration of a Standard Operating Procedure (SOP) for the in vitro 
alkaline comet assay, and to elaborate a SOP for the in vivo alkaline comet assay 
performed either in fresh or frozen tissue, to be later applied in genotoxicology studies 
performed under Good Laboratory Practice (GLP) conditions.  
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Abstract  
The in vivo comet assay is usually performed in fresh tissues by processing cells immediately 
after collection, an approach that is not always possible from a logistical point of view. 
Although the comet assay has been applied to frozen rodent tissue samples on several 
occasions, there is currently no agreement on the best way to freeze and thaw them. 
Furthermore, the In vivo Mammalian Alkaline Comet Assay OECD (TG 489) Guideline requires 
the demonstration of the laboratory’s proficiency in freezing methodologies. In this regard, we 
have not only tested different freezing/thawing procedures in liver tissues from untreated rats, 
but we have also compared the levels of DNA strand breaks and Fpg-sensitive sites between 
fresh and 1-week or 1-month frozen liver, kidney and lung tissue samples from untreated and 
MMS-treated rats. Among the five different procedures tested, only one approach gave 
acceptable results, leading to the conclusion that the thawing process is equally or even more 
determinant than the freezing one in the preservation of DNA integrity. Using this approach, 
our results show that comparable levels of SBs and net Fpg-sensitive sites are detected either 
in fresh or in frozen liver, kidney and lung tissue samples. 
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1. Introduction 
The single-cell gel electrophoresis (comet) assay is a genotoxicity assay which, due to its 
various advantages, has been widely used in several areas, such as in vitro and in vivo 
genotoxicity testing.  
As a result of the first formal validation trial, coordinated by the Japanese Center for the 
Validation of Alternative Methods (JaCVAM) between 2006-2012 (Uno et al., 2015a, 2015b), an 
In vivo Mammalian Alkaline Comet Assay OECD Guideline was achieved (the first version was 
approved in 2014, while the last one was adopted on 29th July 2016) (OECD, 2016). Nowadays, 
the assay is part of the strategy suggested by the International Council on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (ICH, 2012) 
and it is also contemplated by the European Food Safety Authority (EFSA) for the genotoxicity 
testing of compounds in food and animal feedstuffs (EFSA, 2011).  
The in vivo comet assay is usually performed in fresh tissues by processing cells immediately 
after collection, an approach that is not always possible from a logistical point of view due to 
the high number of samples that need to be handled (Brunborg et al., 2014; Pant et al., 2014). 
Moreover, it is advisable to integrate the in vivo comet assay into repeated-dose toxicity 
studies (Recio et al., 2012; Rothfuss et al., 2011) or to perform it in combination with the 
micronucleus assay (Recio et al., 2010). Thereby, freezing of tissues for later analysis emerged 
as an option to overcome the logistic problems. Although the OECD guideline recognises that 
tissues or cell nuclei have been successfully frozen for later analysis, it also requires the 
demonstration of the laboratory’s proficiency in freezing methodologies (OECD, 2016). 
In the literature, the comet assay has been applied to several frozen rodent tissue samples as 
liver (e.g., Folkmann et al., 2007; Jackson et al., 2013; Knudsen et al., 2015; Løhr et al., 2015; 
Risom et al., 2007), kidney (e.g., Knudsen et al., 2015), lung (e.g., Folkmann et al., 2007; 
Jackson et al., 2013; Knudsen et al., 2015; Risom et al., 2007), brain (e.g., Forsberg et al., 2015; 
Knudsen et al., 2015) and spleen (e.g., Knudsen et al., 2015). Moreover, all these studies 
performed the comet assay in combination with enzymes (i.e., Formamidopyrimidine-DNA 
glycosylase, Fpg; Endonuclease III, Endo III; or 8-oxoguanine DNA glycosylase, OGG1).  
According to the OECD Guideline, there is currently no agreement on the best way to freeze 
and thaw tissues (OECD, 2016). Small tissue samples are most commonly snap frozen in liquid 
nitrogen and stored at -80°C until further processing (Folkmann et al., 2007; Forsberg et al., 
2015; Jackson et al., 2013; Knudsen et al., 2015; Løhr et al., 2015; Risom et al., 2007). 
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However, several authors freeze tissue samples as cell suspensions using DMSO as a 
cryoprotectant (Hu et al., 2002; kraynak et al., 2015; Pant et al., 2014; Recio et al., 2010). 
According to our knowledge, Jackson and colleagues have been the only group that has 
thoroughly described both the freezing and thawing process (including the preparation of cell 
suspensions from frozen tissues) (Jackson et al., 2013). Actually, they tested four different 
freezing/thawing methods for liver samples from untreated mice. Their results showed that 
snap freezing in liquid nitrogen of small pieces (i.e., 3 x 3 x 3 mm) of tissue (previously placed 
in cryotubes), in combination with the disgregation of the deep-frozen tissue (i.e., avoiding it 
to thaw) in ice-cold Merchant’s medium using a metal sieve, gave very low levels of DNA 
strand breaks (SBs). On the other hand, leaving the samples to thaw at room temperature 
yielded very high levels of DNA SBs. Moreover, this is the only work in which the comparison 
between fresh and immediately frozen tissues has been done; specifically, they compared the 
results obtained with the standard comet assay in fresh and frozen liver and lung tissues from 
mice treated intraperitoneally with different concentrations of methyl methanesulfonate 
(MMS). Results showed a high correlation between DNA damage and MMS concentration. 
Overall, no significant differences were observed between fresh and frozen tissues, except a 
significant slight increase of the % tail DNA in frozen lung tissue from untreated animals in 
comparison with the freshly-prepared one (from 2.9 to 7.1%).   
In this work, we have explored different freezing/thawing methods to analyse their impact not 
only on the level of DNA SBs, but also on the Fpg-sensitive sites (i.e., oxidised and alkylated 
bases) detected in liver tissues from untreated rats. In addition, we have compared the levels 
of these lesions in fresh and frozen liver, kidney and lung tissues from rats exposed to different 
concentrations of MMS.   
2. Materials and methods  
2.1. Chemicals and reagents 
Low melting point agarose, standard agarose, Triton X-100, Tris base, HEPES, Na2EDTA, BSA, 
MMS and 4’,6-diamidino-2-phenylindole (DAPI) (Item No. D9542, Sigma) were purchased from 
Sigma-Aldrich. NaCl, NaOH, Na2HPO4, KH2PO4 and KCl were purchased from PanReac 
AppliChem and DPBS 1x for mixing cell suspensions with agarose was purchased from Gibco. 
DPBS without Ca+2 and Mg+2 10x from Lonza was used to prepare PBS 1x washing solutions for 
comet assay slides. Fpg was a gift from NorGenoTech (Norway). 
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2.2. Animals 
For step 1 (see next section), in which liver tissues were analysed, untreated rats from other 
toxicological studies were used. These studies were approved by the Ethics Committee on 
Animal Experimentation of the University of Navarra. The use of this material is in agreement 
with the ‘three Rs’ (Reduce, Refine and Replace) strategy for experimental animals. 
For step 2 (see next section), fifteen male Wistar rats, 8 weeks-old, were purchased from 
Charles River. Animals were randomly distributed in groups of five animals per cage and used 
after 1 week of acclimatization under standard conditions (temperature 22 ± 3°C, humidity 50 
± 20%, 12 h light/dark cycle). Animals were fed with standard laboratory chow and allowed to 
access ad libitum feed and drinking water.  
Each day, one animal of each group was orally administered 5 or 200 mg/kg b.w. of MMS, or 
nothing (negative control group). Three hours after the administration, animals were 
anesthetised with isoflurane, sacrificed by cervical dislocation and their liver, kidneys and lungs 
were removed and processed as described below. 
This study was approved by the Ethics Committee on Animal Experimentation of the University 
of Navarra. 
2.3. Sample processing  
The study was performed following a two-step process. The aim of step one was to select the 
best freezing/thawing procedure using liver samples from untreated rats. In step 2, the best 
procedure was applied to liver, kidney and lung samples from untreated and MMS-treated rats 
and a stability study of the frozen samples was performed. 
2.3.1. Step 1  
For step 1, 3 x 3 x 3 mm liver pieces from untreated rats were obtained directly at necropsy by 
cutting the liver on an ice-cold Petri’s dish. Five different approaches were followed by 
combining different freezing/thawing procedures (Figure 1). Regarding the freezing process, 4 
procedures were followed: 1.- flash freezing in liquid nitrogen after transferring them into 
cryotubes and storage at -80°C (approaches 1 and 2); 2.- flash freezing in isopentane cooled in 
liquid nitrogen after transferring them into cryotubes and storage at -80 °C (approach 3); 3.- 
overnight immersion in 4°C Merchant’s medium (0.14 M NaCl, 1.47 mM KH2PO4, 2.7 mM KCl, 
8.1 mM Na2HPO4, 10 mM Na2EDTA, pH 7.4) , transferring to an empty bijou on ice and storage 
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at -80°C (approach 4); 4.- overnight immersion in 4°C RNA later® solution, transferring to an 
empty bijou on ice and storage at -80°C (approach 5).  
For the thawing process, 2 different procedures were used. The first one was used as part of 
approach 1. Cryotubes were placed on dry ice and a drop of Merchant’s medium was placed 
on the tissue to create a protective ice cap. The deep-frozen tissue was transferred into the 
cylindrical metal sieve, previously immersed in 3 mL ice-cold Merchant´s medium, using cold 
tweezers and homogenised by moving a plastic plunger up and down several times, forcing it 
to pass through the sieves. In this way, a cellular suspension was obtained and left on ice until 
comet assay analysis. During all this process samples were kept on ice. 
The second thawing procedure was used as part of approaches 2, 3, 4 and 5: frozen samples 
were immediately put on ice, washed in a beaker with ice-cold Merchant’s medium, 
transferred to another beaker with ice-cold Merchant’s medium, cut into pieces with scissors, 
homogenised using a cylindrical metal sieve (i.e., a stainless steel cylindrical tube of 15 mm 
diameter with a stainless-steel screen of 0.4 mm fitted inside) by moving a plastic plunger up 
and down several times, filtered through a 100 µm nylon filter, centrifuged for 5 minutes at 
214 x g and 4°C and resuspended in Merchant’s medium (centrifuged twice) . 
Several samples were analysed using approach number 1. 
Fresh vs. frozen tissues 
77 
 
 
Figure 1. Schematic diagram of the different freezing and thawing procedures tested in liver 
samples.  
2.3.2. Step 2  
Fresh and frozen liver, kidney and lung tissue samples from rats administered orally with 5 or 
200 mg/kg b.w. of MMS, and non-administered ones were used. One animal of each group was 
administered and sampled each day of the week and animals were sacrificed 3 hours after the 
administration. 
The freezing and thawing procedures were performed using the successful approach from step 
1 (approach 1). Frozen samples were processed after 1 week and 1 month. (Frozen samples 
after 3 months, 6 months and 1 year are under currently analysis; results will be included in 
the manuscript before its submission).  
The standard comet assay was applied to fresh and frozen liver, kidney and lung tissue samples 
from animals of the 3 different groups (i.e., untreated rats, rats treated with 5 mg/kg b.w. of 
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MMS, and rats treated with 200 mg/kg b.w. of MMS). In addition, the comet assay in 
combination with Fpg was applied to fresh and frozen liver, kidney and lung tissue samples 
from rats either untreated or treated with 5 mg/kg b.w. of MMS. 
2.4. Comet assay 
Thirty microliters of the cellular suspension of each sample were mixed with 140 μL of 1% low 
melting point agarose in PBS at 37°C. Immediately, two drops of 70 μL each were placed on a 
glass microscope slide (pre-coated with 1% normal melting point agarose in distilled water and 
dried) and covered with 20 x 20 mm coverslips. Gels were set on a metal plate on ice for 3 min 
and the coverslips were removed. Three slides were prepared per condition: ‘lysis’, ‘buffer’ 
and ‘Fpg’.  
Overnight lysis at 4 °C was performed by immersion in lysis solution (2.5 M NaCl, 0.1 M 
Na2EDTA, 10 mM Trizma® base, pH 10.0, 1% Triton X-100). After lysis, ‘Fpg’ and ‘Buffer F’ slides 
were washed three times (5 min each) with the Fpg reaction buffer (40 mM HEPES, 0.1 M KCl, 
0.5 mM Na2EDTA, 0.2 mg/mL bovine serum albumin, pH 8.0—Buffer F) at 4°C. Afterwards, gels 
were incubated with Buffer F or Fpg by adding a drop of 45 µL of the solutions on top of the 
corresponding ones. Each drop was covered with a 22 x 22 mm coverslip and the gels were 
incubated in a humidified atmosphere at 37°C for 30 min. ‘Lysis’ slides were kept immersed in 
the lysis solution during the washes and the Buffer F/Fpg incubation.   
Alkaline unwinding of all slides was then performed by immersion in an alkaline buffer (0.3 M 
NaOH, 1 mM Na2EDTA, pH >13) at 4°C for 40 min. After that, electrophoresis was performed in 
the same buffer at 1.2 V/cm and 4°C for 20 min. Slides were neutralised with PBS for 10 min at 
4°C, washed in distilled water for another 10 min at 4°C and air-dried at room temperature.  
DNA in each gel was stained with 1 μg/mL DAPI, and comets were visualised under a 
fluorescence microscope (NIKON Eclipse 50 i). DNA damage was quantified in 100 randomly 
selected comets per slide (50 comets in each gel) by measuring the % tail DNA using the image 
analysis software Comet Assay IV (Perceptive Instruments Ltd). For each slide, the median 
value of the % tail DNA was calculated. DNA SBs and alkali-labile sites (ALS) are measured in 
the ‘Lysis’ slide, while Fpg-sensitive sites were calculated by subtracting the median value of 
the ‘Buffer F’ slide from the one obtained in the ‘Fpg’ slide.  
2.4.1. Assay controls 
Positive and negative assay controls were included in each electrophoresis run to assess the 
correct performance of the assay and the inter-assay reproducibility. Positive assay controls 
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were produced by treating TK6 cells, a human-derived lymphoblastoid cell line, with a) 50 µM 
MMS for 3 hours to induce oxidised bases or b) 300 µM MMS for 3 hours to induce DNA SBs. 
Untreated cells were used as negative assay controls. They were prepared, frozen in aliquots 
and tested (to check if they contained the expected levels of DNA lesions) 1 week before each 
of the time points (except for the analysis of 1-week frozen samples, in which the assay 
controls prepared for the analysis of fresh tissues were used). Inclusion of these controls 
would allow the normalization of the data in case of abnormalities in the results due to 
technical problems.  
2.5. Statistics 
Non-parametric U-Mann-Whitney tests were performed to compare the results obtained 
between fresh and frozen tissues.  
3. Results 
3.1. Step 1  
The results obtained after the different freezing/thawing methods applied to liver tissue 
samples from untreated animals are shown in Table I. As it can be seen, only approach 1 gave 
acceptable DNA SBs and Fpg-sensitive sites levels (these results come from several 
independent analysis). Due to the high levels of DNA SBs obtained following approaches 2, 3, 4 
and 5, the results of the comet assay in combination with Fpg could only be obtained in 
samples processed following approach 1. 
Table I. Levels of SBs + ALS and Fpg-sensitive sites obtained after processing liver samples from 
untreated animals using the different approaches (i.e., freezing and thawing procedures).  
Approach SBs + ALS  
(% tail DNA) 
Fpg-sensitive sites 
(% tail DNA) 
1 4.32 ± 3.58 (n=6) 10.43 ± 2.56 (n=2) 
2 ~ 90 -- 
3 ~ 90 -- 
4 82.3 -- 
5 43.7 -- 
 
3.2. Step 2 
Fresh and frozen liver, kidney and lung tissue samples from untreated rats or rats administered 
with 5 or 200 mg MMS/kg b.w., by oral gavage were used. Frozen tissues were snap frozen in 
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liquid nitrogen and stored at -80°C until comet assay analysis. Samples were processed after 1 
week and 1 month, and the thawing process was performed following approach 1.  
Assay controls from one experiment in which 1-month frozen samples were analysed, showed 
a high deviation from the expected % tail DNA. This experiment was discarded due to obvious 
technical problems related to the performance of the comet assay. Moreover, it was not 
possible to analyse a slide corresponding to 1-month frozen liver tissue of an animal treated 
with 200 mg MMS/kg b.w., as it showed a lot of debris.   
The levels of DNA SBs + ALS and Fpg-sensitive sites of liver, kidney and lung tissue samples 
from untreated animals are shown in Figure 2. The levels of DNA SBs were similar in fresh and 
frozen tissues in all cases. A slight but significant increase in the Fpg-sensitive sites was 
observed in 1-month frozen kidney when compared with fresh tissues. A similar slight but 
significant increase was also seen in 1-week but not in 1-month frozen lung tissues. In any 
case, the observed values can be considered within the normal range for control values. 
 
Figure 2. Individual levels of DNA SBs and Fpg-sensitive sites (% tail DNA) found in fresh, 1-
week and 1-month frozen (at -80°C) liver (A), kidney (B) and lung (C) tissue samples from 
untreated animals. *p <0.05 (frozen vs. fresh tissue). n=5, except for 1-month frozen tissues 
(n=4). 
In the case of animals treated with 5 mg MMS/kg b.w., a significant increase in the DNA SBs 
was observed in 1-week frozen lung tissues in comparison with the fresh ones (Figure 3C). 
Nevertheless, this effect was not observed for 1-month frozen tissues. Frozen liver and kidney 
showed similar levels of DNA SBs than the fresh ones (Figure 3A and 3B). Regarding Fpg-
sensitive sites, a statistically significant decrease was seen in 1-week frozen kidneys compared 
with the fresh ones, but this difference was not observed after 1 month of freezing (Figure 3B). 
Frozen liver and lung showed similar levels of Fpg-sensitive sites than the fresh ones (Figures 
3A and C).  
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Figure 3. Individual levels of DNA SBs and Fpg-sensitive sites (% tail DNA) found in fresh, 1-
week and 1-month frozen (at -80°C) liver (A), kidney (B) and lung (C) tissue samples from rats 
treated with 5 mg MMS/kg b.w. *p <0.05 (frozen vs. fresh tissue). n=5, except for 1-month 
frozen tissues (n=4). 
Finally, no differences in DNA SBs were observed between fresh and frozen tissues of animals 
administered with 200 mg MMS/kg b.w. (Figure 4).   
 
Figure 4. Individual levels of DNA SBs (% tail DNA) found in fresh, 1-week and 1-month frozen 
(at -80°C) liver (A), kidney (B) and lung (C) tissues from rats treated with 200 mg MMS/kg b.w. 
*p <0.05 (frozen vs. fresh tissue). n=5, except for 1-month frozen liver (n=3), kidney (n=4) and 
lung (n=4). 
Control assay results from the 17 independent experiments which were performed to analyse 
all the samples are shown in Figure 5. Results are shown by plotting the control assay results 
from each time point together. As it was mentioned before, one experiment was discarded 
due to a high deviation from the expected % tail DNA in the assay controls. Untreated assay 
controls (i.e., untreated TK6 cells) gave the expected results with low variation in both SBs and 
net Fpg-sensitive sites in all cases (Figure 5A). Positive assay controls for Fpg-sensitive sites 
(i.e., TK6 cells exposed to 50 µM MMS for 3 hours) and for SBs (i.e., TK6 cells exposed to 300 
µM MMS for 3 hours) showed low variation: a slight decrease in the Fpg-sensitive sites (Figure 
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5B) and a slight increase in the DNA SBs were observed in the assay controls used for the 
analysis of the 1-month frozen samples (Figures 5B and 5C, respectively).  
 
Figure 5. DNA SBs and Fpg-sensitive sites (% tail DNA) of TK6 cells untreated (A), treated with 
50 µM MMS for 3 hours to induce oxidised bases (measured as Fpg-sensitive sites) (B) or 
treated with 300 µM MMS for 3 hours to induce DNA SBs (C). Values are shown as mean ± SD 
(fresh: n=6; 1 week: n=6 and 1 month: n=5) 
In this study, normalization could be performed by correcting the data of an experiment using 
a correction factor. This correction factor is calculated by dividing the actual assay controls 
results (i.e., from the experiment that is being normalized) by the expected assay control 
result. As expected assay controls, the data obtained in previous experiments in which the 
frozen assay controls are tested (data not shown) or, more commonly, the mean of all the 
assay control results, can be used.  Normalization is done separately for SBs and Fpg-sensitive 
sites taking into account the correspondent assay control values. This normalization process 
will be carried out when finishing the analysis of the frozen samples after 3 and 6 months, and 
1 year at -80°C. Anyway, according to the variation seen in the assay controls, normalization is 
not expected to have a big impact in the presented data. 
4. Discussion  
Taking into account the results obtained when testing the different freezing/thawing 
procedures, approach 1 was found to be the optimal one for the analysis of frozen liver 
samples form untreated animals (Figure 1, Table I). It implies snap freezing in liquid nitrogen of 
a small piece of liver tissue in a cryotube, storage of the sample at -80°C and avoiding tissue 
thawing until getting a cell suspension in a cold environment on the day of comet analysis. This 
approach gave acceptable background levels of DNA SBs (% tail DNA = 4.32 ± 3.58, n=6), being 
within the recommended range for the group mean % tail DNA of liver tissues from vehicle-
treated animals (i.e., not exceeding 6% tail DNA; OECD, 2016), and net Fpg-sensitive sites (% 
tail DNA = 10.43 ± 2.56, n=2) (Table I). However, the rest of the approaches (2, 3, 4 and 5) gave 
Fresh vs. frozen tissues 
83 
 
such high levels of DNA SBs that the Fpg-modified assay could not even be applied (Table I). All 
these approaches included thawing of the tissue at room temperature, thus indicating that the 
way the tissue is thawed is crucial. However, since snap freezing of tissues in liquid nitrogen, 
the most simple and quickest way of freezing samples, gave good results in combination with 
the thawing procedure described above (i.e., approach 1), the combination of the freezing 
procedures of approaches 2 to 5 with the successfully thawing procedure from approach 1 was 
not tested.   
The same effect was observed by Jackson and colleagues after testing four different 
freezing/thawing procedures on the DNA SBs of liver tissues from untreated animals (Jackson 
et al., 2013). They obtained acceptable background levels when small pieces of tissue were 
frozen in liquid nitrogen, stored at -80°C and processed in a cold environment preventing the 
tissue samples to thaw until a cell suspension was obtained (% tail DNA = 6.15 ± 1.62, n=5). 
However, freezing big pieces of tissue and cutting or crushing them before being processed 
significantly increased DNA SBs. On the other hand, thawing of the tissues gave very high levels 
of SBs (% tail DNA = 67.28 ± 20.14, n=5). 
As mentioned in the introduction, the comet assay, both in its standard version and in 
combination with Fpg, has been applied to frozen tissues from different organs in several 
occasions. Nevertheless, a comparison between the analysis of fresh and frozen tissues has 
only been done once and regarding DNA SBs in liver and lung from untreated and MMS-
treated mice (Jackson et al., 2013). The authors compared DNA SBs in fresh and frozen liver 
and lung tissues from untreated and MMS-treated mice (25, 75 and 112.5 mg MMS/kg b.w.), 
but, unfortunately, the time frozen samples were kept at -80°C was not specified.  They found 
a slight but significant increase in frozen lung controls when compared with the fresh ones 
(though values can be considered within the normal range for untreated animals). Moreover, 
they showed that leaving the tissues inside a cryotube at room temperature for 15 min before 
snap freezing in liquid nitrogen did not affect the DNA damage levels substantially (a significant 
increase in the % tail DNA was only seen in liver and lung samples from untreated animals).  
In the present work, for the first time, we have compared the levels of both DNA SBs and net 
Fpg-sensitive sites in fresh and frozen liver, kidney and lung from untreated and orally MMS-
treated rats (5 mg MMS/kg b.w. to induce measurable Fpg-sensitive sites and 200 mg MMS/kg 
b.w. to induce SBs). The analysis of frozen samples was done after storing the samples for 1 
week and 1 month at -80°C. As it is mentioned in the Materials and Methods section, analysis 
of samples which have been kept frozen for 3 months, 6 months and 1 year is still ongoing; 
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those results will be included in the manuscript before its submission. Assay controls which 
consisted in untreated and MMS-treated TK6 cells were included in each experiment to assess 
the technical variability of assay (inter-experimental variation).  
We did not find any increase in the DNA SBs of liver, kidney or lung tissues from untreated 
animals after 1 week or 1 month at -80°C (Figure 2). Moreover, the group mean % tail DNA is 
lower than 6% tail DNA for liver tissues in all cases (i.e., fresh, 1-week and 1-month frozen 
tissues), as recommended by the OECD Guideline for liver tissues of vehicle-treated animals (it 
does not provide recommendation for other tissues) (OECD, 2016). However, we observed a 
slight but significant increase on the Fpg-sensitive sites of frozen kidney (1 week) and lung (1 
month) tissues (Figure 2B). In all cases, values were within the normal range for control values. 
Moreover, in the case of the kidney, the increase was seen after 1 week at -80°C but not after 
1 month, thus indicating that the observed increase is probably not relevant (Figure 2B). In the 
case of animals treated with 5 mg MMS/kg b.w., a significant decrease in the Fpg-sensitive 
sites was observed in 1-week frozen kidney samples in comparison with the fresh ones (Figure 
3B). The relevance of this finding is debatable since the level of Fpg-sensitive sites observed in 
1-month frozen kidney samples is similar to the levels of the fresh ones (the same 
phenomenon occurs with the levels of DNA SBs in lung tissue samples). Finally, no statistically 
significant differences were found in the SBs level between fresh and frozen liver, kidney and 
lung tissue samples of animals treated with 200 mg MMS/kg b.w. (Figure 4).  
Assay controls were included in order to detect technical problems and to assess the comet 
assay’s variation (Figure 5). Moreover, the inclusion of these controls allows data 
normalization to remove (at least partially) the technical inter-experimental variation. As it was 
mentioned before, this approach allowed us to discard one of the experiments due to 
anomalous results in these controls. In all other experiments, negative controls gave the 
expected results, while both SBs and Fpg-sensitive sites positive controls showed a low-
moderate variation. Though normalization of results will be carried out when the analysis of 
the 3-, 6-months and 1-year frozen samples is completed, up to now it seems that the 
obtained data will not be substantially affected. 
As mentioned in the introduction, although the OECD guideline recognises that tissues or cell 
nuclei have been successfully frozen for later comet assay analysis, it also requires the 
demonstration of the laboratory’s proficiency in freezing methodologies (OECD, 2016). We 
have moved a step forward, also applying the Fpg-modified comet assay to 1-week or 1-month 
frozen tissue samples in order to detect other types of DNA lesions. This approach is not even 
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covered for fresh tissues in the OECD Guideline, as according to the OECD those necessary 
protocol modifications still need to be adequately characterised (OECD, 2016). 
As it is mentioned in the introduction, some authors freeze tissue samples as a cell suspension 
using DMSO as a cryoprotectant. Applying the comet assay to frozen cell suspensions led to 
high % tail DNA values in the liver and duodenum of vehicle-treated male B6C3F1 mice and 
male Fisher 344/N rats (Recio et al., 2010). Pant et al. (2014) found a significant increase in the 
% tail DNA of frozen cell suspensions, prepared from male liver and male and female kidney of 
vehicle-treated animals, to levels above their fresh liver historical control ranges, but they do 
not show their historical control range for kidney. Freezing female liver, and male or female 
stomach cell suspensions had no effect on the background % tail DNA (Pant et al., 2014). 
Although cell suspensions were frozen using 10% DMSO in these three studies, it is important 
to bear in mind that they were also allowed to thaw (at least partially) before slide preparation 
(Pant et al., 2014; Recio et al., 2010). However, rapid thawing (in a 37°C water bath) and 
processing of frozen liver cell suspensions of untreated, treated with EMS, 2-
acetylaminofluorene (AAF) or cisplatin (CPN) Sprague-Dawley rats (or in vitro ɣ-irradiated), 
gave comparable results to those obtained with fresh preparations (Kraynak et al., 2015). In 
the same way, Hu et al. (2002) showed no significant differences in DNA SB levels measured as 
tail moment in fresh and 72 h-frozen liver and kidney tissues (-85°C) of untreated and ferric 
nitriloacetate (Fe/NTA)-treated Sprague-Dawley rats (tissues were digested with collagenase 
after thawing the samples in a water bath).   
Freezing of tissues as cell suspensions may be a good option, or even the only one, depending 
on the tissue. However, this approach might not be the most optimal in order to overcome the 
logistical problems due to the handling of a huge number of samples when evaluating multiple 
tissues from many animals, or when performing the assay in combination with other toxicity 
assays.  
Preparation of specimens in a timely fashion is a critical variable which may affect the results 
obtained in the comet assay (OECD, 2016), as DNA repair might act as a confounder if samples 
are maintained fresh (Guerard et al., 2014; Knudsen et al., 2005), or extrinsic DNA damage 
could be added if it is done under inappropriate conditions (Guerard et al., 2014). In principle, 
freezing of tissues would allow to maintain a constant and acceptable length of time for the 
preparation of the specimens, thereby helping to reduce variation due to the processing of 
several samples.  
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As it can be concluded from our results, the thawing process seems to be a major risk factor, 
equally or even more determinant than the freezing process in the preservation of DNA 
integrity, as it has been shown to dramatically increase the DNA damage detected in liver 
samples from untreated animals. Thereby, although it is possible to apply the comet assay to 
frozen tissue samples, extreme caution is needed to avoid unintentional thawing of the 
samples while processing them. Our results show that the levels of SBs and net Fpg-sensitive 
sites detected in frozen liver, kidney and lung are comparable to the levels observed in fresh 
tissues. As it has been mentioned along this document, the stability study of the frozen 
samples is undergoing.   
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Abstract 
Ochratoxin A (OTA) is a mycotoxin considered the most powerful renal carcinogen in rodents 
and classified as a possible human carcinogen. Though its mechanism of action is still 
unknown, indirect DNA reactivity mediated by oxidative stress has been hypothesised to play 
an important role. Moreover, large sex-differences have been observed in carcinogenicity 
studies, being male rats more sensitive than females.  
Male and female F344 rats were administered (p.o.) with bicarbonate or 0.5 mg OTA/kg b.w. 
for 7 days; or with bicarbonate, 0.21 or 0.5 mg OTA/kg b.w. for 21 days. Total glutathione 
(tGSH) and oxidised glutathione (GSSG) levels, glutathione S-transferase (GST) and superoxide 
dismutase (SOD) activities were analysed in kidneys. The standard alkaline comet assay was 
used in combination with Formamidopyrimidine-DNA glycosylase (Fpg) to detect oxidative 
DNA damage in kidney. 
No biologically relevant sex-differences were observed in all the oxidative-stress related 
parameters analysed. Indeed, no relevant oxidative-stress related response was observed 
between treated animals and controls. In accordance with the similar OTA levels and 
histopathological changes between both sexes observed previously in the same animals, and 
with other oxidative-stress related parameters measured by others, results support that there 
are no differences between sexes in the oxidative stress response to OTA. 
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1. Introduction   
Ochratoxin A (OTA) is a secondary fungal metabolite produced by several species of Aspergillus 
and Penicillium. Since this mycotoxin is present in a wide variety of human foodstuff and 
animal feed (EFSA, 2006; WHO, 2008), human exposure can occur both through consumption 
of contaminated food commodities or products from animals fed with contaminated feed 
(NTP, 1989). Thereby, humans are continuously exposed to this mycotoxin (EFSA, 2006; Fink-
Gremmels, 2005). 
OTA has been proposed as a possible etiological agent of the Balkan Endemic Nephropathy 
(BEN) and it has also been associated with an increased incidence of urinary tract tumours in 
humans (Petkova-Bocharova et al., 1988; Pfohl-Leszkowicz et al., 2002; Plestina et al., 1990). 
However, there is still a lack of epidemiological evidence as other factors or co-factors might 
be involved in the aetiology of the diseases (Reddy and Bhoola, 2010). 
OTA nephrotoxicity has been demonstrated in every laboratory species used, and it is also 
considered the most powerful renal carcinogen in rats (Lock and Hard, 2004). The available 
data obtained from different carcinogenicity studies in rodents shows large sex-differences in 
susceptibility towards OTA-induced tumours: dosing Fischer (F344) rats with OTA for 2 years 
produced a ten-fold higher incidence of renal tumours in male rats when compared to female 
rats (Boorman et al., 1992; NTP, 1989), and this sex-biased response has also been observed in 
other studies using Dark-Agouti and Lewis rats (Castegnaro et al., 1998; Son et al., 2003). Other 
studies have deepened into the effect of sex on OTA toxicity in vivo from the toxicokinetic 
point of view (Vettorazzi et al., 2011, 2010, 2009; Zepnik et al., 2003). 
Unfortunately, the exact mechanism of action by which OTA induces tumours is still unknown 
and several hypotheses have been proposed to contribute, totally or partially, to it (WHO, 
2008). Among them, indirect DNA reactivity mediated by oxidative stress has been supported 
by several authors. Several studies have demonstrated that OTA inhibits the nuclear factor, 
erythroid 2-like 2 (Nrf2) oxidative stress response pathway, which would affect glutathione 
synthesis and recycling, oxidoreductases activity, and phase II metabolism inducibility, thus 
rendering the tissue more vulnerable to oxidative stress (Limonciel and Jennings, 2014). A 
downregulation of genes under transcriptional control of Nrf2 was also observed in the kidney 
of rats fed OTA up to 12 months (Marin-Kuan et al., 2006). The effects observed at mRNA level 
were later confirmed as biologically relevant as OTA also decreased the protein expression of 
several markers of the Nrf2-regulated gene battery in kidney in vivo, which resulted in 
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oxidative DNA damage, and in vitro in the NRK renal cell line and in primary hepatocyte 
cultures (Cavin et al., 2007). Arbillaga et al. (2007a), found that several genes implicated in the 
oxidative stress response were up-regulated in the human renal cell line (HK-2) following OTA 
exposure during 6 and 24 h, but identified down-regulation as the predominant effect in a 
repeated-dose study carried out in F344 rats (Arbillaga et al., 2008). A differential expression 
of genes involved in the response to oxidative stress was also seen in vivo and in vitro by Lühe 
et al. (2003). In the same line, using both the Eker rat model of increased susceptibility to renal 
tumour formation and the corresponding wild-type strain, Stemmer et al. (2007) found that 
OTA treatment down-regulated the expression of several phase I and phase II enzymes in both 
strains and deregulated the expression of several genes involved in the response to DNA 
damage (including oxidative stress) in Eker rats. 
On the other hand, other effects related to oxidative stress production have been observed 
after OTA exposure. Omar et al. (1990) came to the conclusion that OTA stimulates lipid 
peroxidation by complexing Fe3+, which may facilitate its reduction, although the specific 
specie responsible for initiating lipid peroxidation was not identified. It has been established 
that OTA leads to lipid peroxidation both in vitro (Klarić et al., 2007) and in vivo (Abdel-
Wahhab et al., 2005; Ferrante et al., 2006; Ozçelik et al., 2004), to a decrease of glutathione 
(GSH) levels in vitro (Klarić et al., 2007; Schaaf et al., 2002) and in vivo (Meki and Hussein, 
2001), and to an increase of the kidney’s protein carbonyl levels after 21 days of OTA-
treatment (Domijan et al., 2005). It has also been observed that OTA causes a dose-dependent 
increase of reactive oxygen species (ROS) (Baldi et al., 2004) as well as oxidative DNA damage 
in vitro (Arbillaga et al., 2007b; Schaaf et al., 2002), and it is considered to significantly increase 
oxidative DNA damage in vivo (Kamp et al., 2005; Mally et al., 2005). OTA exposure to HepG2 
cells decreased the intracellular zinc concentration (considered a potential antioxidant), 
induced ROS production, 8-hydroxy-2’-deoxyguanosine (8-OHdG) formation and decreased 
superoxide dismutase (SOD) activity (Zheng et al., 2013). In fact, treatment of OTA-pretreated 
Wistar rats with SOD and catalase prevented enzymuria, proteinuria, creatinemia and 
increased urinary excretion of OTA (Baudrimont et al., 1994). 
Thus, it appears clear that oxidative stress might be implicated in OTA toxic response. 
However, the influence of sex in OTA-mediated kidney oxidative stress response has not been 
specifically studied. Indeed, this might be an important aspect to evaluate as sex differences 
regarding oxidative stress response have been observed in other scenarios such as after giving 
a high cholesterol diet to Wistar albino rats (Al-Rejaie et al., 2012), acetaminophen to CD-1 
mouse (Hoivik et al., 1995) or cisplatin to Swiss albino mice (Naseem et al., 2015). Besides, 
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Lash et al. (1998) found that the rate of S-(1,2,2-trichlorovinyl) glutathione (TCVG) formation in 
isolated kidney cells from male and female F344 rats were similar, but kidney cytosol and 
microsomes from males exhibited higher amounts of TCVG formation than the corresponding 
fractions from females, for both F344 rats and B6C3F1 mice. Regarding in vitro studies, 
vascular smooth muscle cells (VSMC) isolated from male rat aorta were found to be much 
more susceptible to radiation-induced stress (measured by ROS production) than the female 
ones (Malorni et al., 2008). 
Several studies have measured kidney oxidative stress status using different rat species and 
with different dosages after OTA administration. However, all of them have used male rats. To 
the authors knowledge, only one study (Hibi et al., 2011) analysed oxidative DNA damage (8-
hydroxy-2’-deoxyguanosine levels) in both sexes after 4 and 13 weeks of OTA administration in 
diet (approximately 0.4 mg/kg b.w.). No differences between sexes were found in oxidative 
DNA damage or at histopathological level. This in agreement with our recently published study 
carried out in male and female F344 rats (Pastor et al., 2018), where slightly higher signs of 
toxicity were found in kidney histopathology in males after 7 days of 0.5 mg OTA/kg b.w. daily 
administration but no differences were found after 21 days of treatment.  
Due to the different tumour incidence found between both sexes (NTP, 1989) and the 
evidences suggesting an OTA indirect mechanism of action through oxidative stress, the 
present study aims at measuring different oxidative stress-related parameters such as 
glutathione-S-transferase (GST) activity, total (tGSH) and oxidised (GSSG) glutathione levels 
and superoxide dismutase activity (SOD) in kidney of both male and female F344 rats. 
Moreover, in order to relate these endpoints with oxidative DNA damage, the comet assay in 
combination with Formamidopyrimidine-DNA glycosylase (Fpg) was carried out in kidney 
tissue. 
2. Materials and methods  
2.1. Chemicals and reagents 
Commercial available kits were used for the determination of total (cytosolic and microsomal) 
GST activity (Glutathione S-Transferase Assay Kit®, Item No. 703302, Cayman Chemical), tGSH 
and GSSG glutathione (Glutathione Assay Kit®, Item No. 703002, Cayman Chemical), and SOD 
activity (SOD determination kit®, Item No. 19160, Sigma-Aldrich). For protein quantification, 
Protein Assay Dye Reagent Concentrate (Item No. 500-0006, Bio-Rad) and Standard Bovine 
Serum Albumin (BSA, Item No. A3803, Sigma) were used. The SOD standard from bovine 
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erythrocytes (Item No. S2515), 2-vinylpyridine (Item No. 132292) and EDTA were purchased 
from Sigma-Aldrich. Dulbecco’s Phosphate Buffered Saline (PBS) without Ca+2 and Mg+2 10x 
from Lonza (Item No.BE17-515Q) was used to prepare PBS 1x washing solutions for tissues or 
comet assay slides. Saline for washing tissues for SOD activity determination was purchased 
from Grifols (Item No. 825083). The salts KH2PO4 and K2HPO4·3 H2O used to prepare buffer A 
and B for tissue preparations were obtained from Panreac AppliChem and Merck KGaA, 
respectively.  For sucrose buffer (pH 7.4), 0.25 M sucrose, 10 mM Tris and 1 mM EDTA were 
purchased from Sigma.  
For the comet assay, low melting point agarose, standard agarose, Triton X-100, Tris base, 
HEPES, Na2EDTA, BSA, methyl methanesulfonate (MMS) and 4’,6-diamidino-2-phenylindole 
(DAPI) (Item No. D9542, Sigma) were purchased from Sigma-Aldrich. NaCl, NaOH, Na2HPO4 and 
KCl were purchased from PanReac AppliChem and Dulbecco’s Phosphate Buffered Saline 
(DPBS) 1x (Ref. 14190-094) for mixing cell suspensions with agarose was purchased from 
Gibco. Fpg was a gift from Prof. Andrew Collins (University of Oslo). Ro 19-8022 (Ro), which 
specifically produces oxidised purines (mainly 8-oxo-7,8-dihydroguanine; 8-oxoGua) in the 
presence of visible light, was kindly given by Hoffmann-La Roche. 
2.2. Samples 
This study was carried out using samples obtained in a previous study (Pastor et al., 2018). The 
study was approved by the Ethics Committee on Animal Experimentation of the University of 
Navarra. Briefly, kidneys were obtained from male and female Fischer 344 (F344/IcoCrl) rats 
gavaged daily for 7 days with OTA (0.50 mg/kg b.w.) or vehicle (NaHCO3) (n= 6 per treatment 
group and sex) or for 21 days with OTA (0.21 mg/kg b.w. or 0.50 mg/kg b.w.) or vehicle 
(NaHCO3) (n= 6 per treatment group and sex). Unfortunately, some rats were euthanised for 
ethical reasons while conducting the study. For that reason, for the different determinations of 
the 21-days study, 4 samples of male control group and 5 samples of female group treated 
with 0.21 mg/kg b.w. OTA were available. 
Twenty-four hours after the last administration, animals were sacrificed by decapitation and 
their organs were removed. Left kidneys were longitudinally cut in two halves. One half was 
excised in pieces of approximately 50-100 mg, containing both cortex and medulla. The pieces 
for the subsequent determination of glutathione (tGSH and GSSG) content and GST activity 
were washed in ice-cold PBS (phosphate buffered saline), pH 7.4, and the pieces for the 
subsequent determination of SOD activity were washed with ice-cold saline (0.9% NaCl), to 
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remove any red blood cells and clots. All the pieces were then introduced in labelled 
cryotubes, snap frozen in liquid nitrogen and stored at -80°C until analysis. 
For the comet assay, approximately 2 x 3 x 5 mm kidney samples, containing both cortex and 
medulla, were cut, placed in labelled cryotubes and snap frozen in liquid nitrogen. Samples 
were also stored at - 80°C until the comet assay was performed. 
2.3. Determination of total GST activity 
Total GST activity (cytosolic and microsomal) was spectrophotometrically determined at 340 
nm by measuring the conjugation of 1-chloro-2,4-dinitrobenzene (CDNB) with reduced 
glutathione using a commercial available kit from Cayman Chemical. One unit of enzyme is 
defined as the amount of enzyme able to conjugate 1.0 nmol of CDNB with reduced 
glutathione per minute at 25°C. The assays were performed by using the provided solutions 
and following the kit-included protocol. 
For that purpose, frozen kidney samples were homogenised in 7.5 mL of ice-cold buffer A (100 
mM phosphate, pH 7.0, containing 2 mM EDTA) per gram of tissue, using a Teflon pestle 
homogenizer at 600 rpm. The homogenate was centrifuged at 8000 x g for 15 min at 4°C, and 
the protein concentration of the supernatants was assayed using the Bradford assay by 
extrapolating from known concentrations of standard BSA. For the assay, 6 mg/mL (120 µg) of 
protein were used.   
2.4. Quantification of tGSH and GSSG levels 
Total glutathione (tGSH) (both reduced and oxidised) concentration was 
spectrophotometrically assessed at 405 nm by a recycling method in which reduced 
glutathione (GSH) reacts with DTNB (5,5’-dithio-bis-2-[nitrobenzoic acid], Ellman’s reagent) to 
produce a yellow coloured 5-thio-2-nitrobenzoic acid (TNB) using a commercial available kit 
from Cayman Chemical. Since glutathione reductase is used in the kit, both GSH and GSSG 
glutathione are measured and the assay reflects tGSH. For exclusive determination of GSSG 
the assay was accomplished by first derivatizing with 2-vinylpyridine following the kit 
instructions. 
For that purpose, frozen kidney samples were homogenised in 5 mL of ice-cold buffer B (50 
mM phosphate, pH 6-7, containing 1 mM EDTA) per gram of tissue, using a Teflon pestle 
homogenizer at 600 rpm. The homogenate was centrifuged for 15 min at 8000 x g and 4°C, and 
50 µL of supernatant was used for the determination. Thereafter the protein concentration of 
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the supernatants was assayed using the Bradford assay by extrapolating from known 
concentrations of standard BSA. Following the kit instructions, supernatants were 
deproteinated before assaying tGSH and GSSG levels.  
Quantification of tGSH or GSSG was achieved following the End Point Method calculations 
indicated in the kit and, and results were expressed in nmol/mg protein. 
2.5. Determination of SOD activity 
SOD activity was determined spectrophotometrically by an indirect method using a 
commercially available kit from Sigma. The measurement method is based on the principle 
that xanthine reacts with xanthine oxidase to generate superoxide radicals, which react with a 
highly water-soluble tetrazolium salt (WST-1) to produce a water-soluble formazan dye (WST-1 
formazan). SOD activity is then determined spectrophotometrically at 440 nm by measuring 
the degree of inhibition of this reaction. The assays were performed by using the provided 
solutions and following the kit-included protocol. 
Frozen kidney samples were homogenised in 900 µL of ice-cold sucrose buffer (0.25 M sucrose, 
10 mM Tris, 1 mM EDTA, pH 7.4) per 100 mg of tissue, using a Teflon pestle homogenizer at 
600 rpm. The homogenate was centrifuged for 15 min at 8000 x g and 4°C, and the protein 
concentration of the supernatants was assayed using the Bradford assay by extrapolating from 
known concentrations of standard BSA. For the assay, 0.1 mg/mL (2 µg) of protein were used.   
2.6. Comet assay 
Tissue samples were processed as described by Jackson et al. (2013). The cryotubes containing 
the tissues were placed on dry ice and one sample was processed at a time until cells were 
embedded in agarose. A drop of Merchant´s buffer (0.14 M NaCl, 1.47 mM KH2PO4, 2.7 mM 
KCl, 8.1 mM Na2HPO4, 10 mM Na2EDTA, pH 7.4) was placed on the tissue to create a protective 
icecap. The tissue was then transferred into a cylindrical sieve (i.e., a stainless-steel cylindrical 
tube of 5 mm diameter with a stainless-steel screen of 0.4 mm fitted inside) previously 
immersed in 3 mL ice-cold Merchant’s buffer using cold tweezers. Tissues were homogenised 
by pressing them through the sieves moving a plastic plunger up and down several times. 
Kidney cell suspensions were centrifuged for 5 min at 390 x g and 4°C and the pellet was 
resuspended in 3 mL of ice-cold Merchant´s buffer.  
Thirty microliters of the cellular suspension were mixed with 140 μL of 1% low melting point 
agarose in PBS at 37°C. Immediately, two drops of 70 μL each were placed on a glass 
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microscope slide (pre-coated with 1% normal melting point agarose in distilled water and 
dried) and covered with 20 x 20 mm coverslips. Gels were set on a metal plate on ice and the 
coverslips were removed. Overnight lysis at 4°C was performed by immersing the slides in lysis 
solution (2.5 M NaCl, 0.1 M Na2EDTA, 10 mM Tris-base, pH 10.0, 1% Triton X-100 prior to use). 
Three slides were prepared from each cell suspension: the ‘Lysis’ slide, the ‘Fpg’ slide and the 
‘Buffer F’ slide. After lysis, the ‘Fpg’ and ‘Buffer F’ slides were washed three times (5 min each) 
with the enzyme reaction buffer (40 mM HEPES, 0.1 M KCl, 0.5 mM Na2EDTA, 0.2 mg/mL BSA, 
pH 8.0-Buffer F) at 4°C. A drop of 45 µL of Buffer F or Fpg was added on top of the 
corresponding gels, covered with a 22 x 22 mm coverslip and incubated in a humidified 
atmosphere at 37°C for 30 min. Meanwhile, the ‘Lysis’ slides were kept immersed in the lysis 
solution.   
Alkaline DNA unwinding was performed by immersing the slides in an alkaline buffer (0.3 M 
NaOH, 1 mM Na2EDTA, pH >13) at 4°C for 40 min. After that, 20 min electrophoresis was 
performed in the same buffer at 1.2 V/cm and 4°C. Following electrophoresis, slides were 
washed with PBS for 10 min at 4°C, with distilled water for another 10 min at 4°C and air-dried 
at room temperature. 
Afterwards, DNA in each gel was stained with 30 µL of 1 μg/mL DAPI, and comets were 
visualised under a fluorescence microscope (NIKON Eclipse 50 i). DNA damage was quantified 
in 100 randomly selected comets per slide (50 comets in each gel) by measuring the % tail DNA 
using the image analysis software Comet Assay IV (Perceptive Instruments Ltd). For each slide, 
the median value of the % tail DNA was calculated. DNA strand breaks (SBs) and alkali-labile 
sites (ALS) are measured in the ‘Lysis’ slide, while Fpg-sensitive sites (i.e., an indicator of 
oxidative DNA damage) were calculated by subtracting the median value of the ‘Buffer F’ slide 
from the one obtained in the ‘Fpg’ slide for each tissue sample. For the final results, the mean 
of the median obtained per animal was calculated.  
Positive and negative assay controls were included in each electrophoresis run to assess a 
correct performance of the assay and the inter-assay reproducibility. Positive assay controls 
were produced by treating V-79 cells, derived from Chinese hamster lung fibroblasts, with a) 1 
µM Ro 19-8022 plus light to induce oxidised bases or b) 200 µM MMS to induce DNA SBs. 
Untreated V-79 cells were used as negative assay controls. These controls were prepared and 
frozen in aliquots. 
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Moreover, a sample of each of the treatments from both sexes was included in each 
electrophoresis run to minimize the potential influence of the inter-experimental variation in 
the results.     
2.7. Statistics 
Non-parametric one-way analysis of variance (i.e., Kruskal-Wallis test), followed by Mann-
Whitney multiple-comparison U-tests, were performed to compare the results obtained 
between different doses within the same sex and also to compare between both sexes treated 
with the same dose. 
3. Results  
3.1. GST activity 
No statistically significant differences were found between control and OTA-treated groups or 
both sexes, neither after 7 days nor after 21 days of treatment (Figures 1A and 1B). However, 
GST activity tended to be reduced in the female groups treated with 0.21 or 0.5 mg OTA/kg 
b.w. after 21 days of treatment when compared to the control group (Figure 1B).    
 
Figure 1. GST activity measured in kidney tissue of male and female F344 rats treated with 0 or 
0.5 mg OTA/kg b.w. for 7 days (A) or with 0, 0.21 or 0.5 mg OTA/kg b.w. for 21 days (B). Values 
are shown as average ± SD. 
3.2. tGSH and GSSG levels 
In the 7-days study, tGSH levels in the kidney were higher in female than in male rats, although 
this difference was only statistically significant between control groups (p=0.021 between 
control groups, and p=0.078 between OTA-treated groups). OTA-treatment did not alter tGSH 
levels neither in males nor in females (Figure 2A). 
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Again, in the case of control animals from the 21-days study, females presented statistically 
significant higher levels of tGSH than males (p=0.032). OTA treatment diminished the basal 
sex-differences as a slight dose-dependent increase was observed in males, while in females 
tGSH levels tended to decrease with the treatment. However, no statistically significant 
differences were observed between treated and control groups for both sexes (Figure 2B).  
Regarding GSSG levels, both control and OTA-treated females showed higher levels than males 
at 7 days (Figure 2C). This difference was not observed at 21 days (Figure 2D). OTA treatment 
did not affect GSSG levels in both sexes neither at 7 days nor at 21 days.  
 
Figure 2. tGSH content measured in kidney tissue of male and female F344 rats treated with 0 
or 0.5 mg OTA/kg b.w. for 7 days (A) or treated with 0, 0.21 or 0.5 mg OTA/kg b.w. for 21 days 
(B). GSSG content measured in kidney tissue of male and female F344 rats treated with 0 or 0.5 
mg OTA/kg b.w. for 7 days (C) or treated with 0, 0.21 or 0.5 mg OTA/kg b.w. for 21 days (D).  
Values are shown as average ± SD. *Statistical significance (p <0.05) females vs. males. 
3.3. SOD activity 
OTA treatment for 7 or 21 days did not alter significantly kidney SOD activity levels neither in 
males nor in females. Besides, there were not any statistically significant differences in kidney 
SOD activity levels between males and females (Figure 3). 
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Figure 3. SOD activity measured in kidney tissue of male and female F344 rats treated with 0 or 
0.5 mg OTA/kg b.w. for 7 days (A) or treated with 0, 0.21 or 0.5 mg OTA/kg b.w. for 21 days 
(B). Values are shown as average ± SD. 
3.4. Comet assay 
OTA treatment for 7 or 21 days did not induce a significant increase of the DNA damage, 
neither as DNA SBs (plus ALS) nor as oxidised bases (i.e., Fpg-sensitive sites), in kidney tissue 
from male and female rats (Figures 4A and 4B). Differences between both sexes were also not 
observed.   
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Figure 4. DNA SBs (plus ALS) and Fpg-sensitive sites measured in kidney tissue of male and 
female F344 rats treated with 0 or 0.5 mg OTA/kg b.w. for 7 days (A) or with 0, 0.21 or 0.5 mg 
OTA/kg b.w. for 21 days (B). Results from assay controls with V-79 are also shown. Values are 
shown as mean ± SD. 
4. Discussion  
Low levels of chronic oxidative stress have been associated with carcinogenesis (Klaunig and 
Kamendulis, 2004). A great deal of research carried out until today supports that OTA 
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mechanism of action is related with a certain degree of oxidative stress (reviewed by Marin-
Kuan et al., 2011). Even if some hypotheses have been proposed (Cavin et al., 2007; Limonciel 
and Jennings, 2014), the exact role of oxidative stress in OTA-induced renal carcinogenesis 
remains unknown.  
What seems to be clear is that OTA induced a higher incidence of kidney tumours in male rats 
than in females (Castegnaro et al., 1998; NTP, 1989; Son et al., 2003). Thus, the aim of the 
present study was to evaluate the antioxidant response of both males and females after 
exposure to OTA doses (0.21 and 0.5 mg/kg b.w.) known to produce renal tumours in 2 years-
bioassays (Castegnaro et al., 1998; NTP, 1989). For that purpose, kidney samples from F344 
rats treated for 7 and 21 days with OTA by gavage (from Pastor et al., 2018) were analysed for 
GSH levels, GST and SOD activity and DNA damage evaluated by the comet assay.  In Pastor et 
al. (2018) and, more concretely, in the same samples evaluated in the present study, several 
sex-differences related with kidney transporters regulation were observed. However, OTA 
concentration in plasma and kidneys was similar in both sexes. Histopathology revealed that, 
after 7 days of treatment with 0.50 mg OTA/kg b.w., the number of animals or the intensity of 
glomerulonephritis, tubulonephrosis or alterations in the collecting ducts was slightly higher in 
males than in females. However, after 21 days, even if the incidence or the severity of the 
lesions increased in both sexes, sex differences disappeared for the two doses evaluated. In 
the present study, no biologically relevant sex-differences were observed in all the oxidative-
stress related parameters analysed: total GST activity, tGSH and GSSG levels, SOD activity and 
oxidative DNA damage. Indeed, no relevant oxidative stress related response was observed 
between treated animals and controls.  These results are in agreement with an in vivo study 
carried out with OTA in male and female rats (Hibi et al., 2011), where no differences related 
with oxidative stress damage (measured as nuclear 8-OHdG) were observed neither between 
rats fed 5 ppm OTA for 4 weeks and controls nor between both sexes. Equally, no differences 
at histopathological level were observed.  
In the present study, GST activity was evaluated as it is a well-known phase II-metabolism 
enzyme that plays a key role in cellular detoxification. It conjugates xenobiotics to glutathione, 
thereby neutralizing their electrophilic sites, and rendering the products more water-soluble in 
order to excrete them. This enzyme, together with GSH, might also play a role in the metabolic 
fate of OTA. Indeed, some authors considered that a small portion of OTA bioactivates into 
hydroquinone (OTHQ) and quinone (OTQ) derivatives, that are in turn further metabolised into 
glutathione conjugates (OTHQ-GSH) (Dai et al., 2002). This reaction has been proposed to be 
also catalysed by GSTs by some authors (Pfohl-Leszkowicz and Castegnaro, 2005). Some 
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authors have proposed that ROS could be produced during this reaction (Gillman et al., 1999). 
Unfortunately, even though certain GST polymorphisms have been associated with an 
increased risk of Balkan Endemic Nephropathy (Reljic et al., 2014), a human disease that has 
been partially related to OTA exposure, and with an increased DNA damage (Lebrun et al., 
2006), the role of GST has not been deeply explored in relation to OTA mechanism of action. In 
the present study, no statistically significant sex-differences in GST activity have been 
observed. However, a tendency to a dose-dependent decrease of GST activity was observed 
mainly in females treated with OTA after 21 days. In the hypothetic situation that GST activates 
OTA to more DNA-reactive quinone derivatives, our result would support a slight tendency to 
lower production of these metabolites in females (less sensitive to tumour formation than 
males). Indeed, Tozlovanu et al. (2012) found that Dark-Agouti male rats generate higher levels 
of GSH-OTA conjugates than females. But, due to the fact that GST might also reduce free 
radicals, males could be more effective fighting against oxidative stress. Due to the conflicting 
results on the role of GSH in OTA toxicity (reviewed by Turesky, 2005) its levels were also 
measured in the present study in both sexes. Slightly higher levels of tGSH were detected in 
control females than in males. Even if not statistically significant, a slight dose-dependent 
increase of tGSH was observed in OTA-treated males, while females tended to show a dose-
dependent decrease. In general, the sex-differences observed in the present study are too 
slight to consider them as biologically relevant and might be within the normal physiological 
levels. In addition, no differences regarding SOD activity were observed between control and 
OTA treated animals, as well as between sexes. SOD activity was evaluated as it is an important 
enzyme involved in oxidative stress detoxification that has been shown to be related to OTA 
nephrotoxicity (Baudrimont et al., 1994; Ciarcia et al., 2016). 
Our results are in accordance with several in vivo studies carried out with OTA in males. Chong 
and Rahimtula (1992) concluded that there were no significant changes in GST and SOD 
activities in kidney cortex supernatants of Sprague-Dawley rats treated daily for 4 days with 
0.5, 1 or 2 mg OTA/kg b.w., nor in cytosol isolated from rats 10 min to 6 h after a single dose of 
10 mg OTA/kg b.w. Accordingly, another acute oral treatment of male F344 rats (up to 2 mg 
OTA/kg b.w., 24 h) (Gautier et al., 2001) did not induce an increase in the lipid peroxidation 
marker malondialdehyde in rat plasma, kidney and liver, nor in the DNA damage marker 8-oxo-
7,8-dihydro-2’-deoxyguanosine (8-oxodG) in kidney. Žlender et al. (2009) also did not find 
differences in GSH (and 8-OHdG levels) in kidneys from OTA-treated rats by gavage at different 
doses for 10 days. Moreover, more recently Taniai et al. (2014) and Qi et al. (2014), using 
similar experimental designs to ours (F344 male rats, 0.21 mg OTA/kg b.w. in NaHCO3 for 28 
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days) did not find significant differences in tGSH nor in GSSG levels between OTA-treated and 
control animals. Moreover, at this timepoint, Qi et al. (2014) did not find differences in SOD 
activity nor in other oxidative stress related parameters (i.e., ROS, malondialdehyde or 8-
OHdG) as well as DNA SBs in the comet assay.   
In contradiction to our results interpretation, Palabiyik et al. (2013) found a significant 
decrease of GSH levels and an increase of SOD activity in male Sprague-Dawley rats treated 
with 0.5 mg OTA/kg b.w. (dissolved in corn oil and 10% DMSO) for 14 days. On the other hand, 
using the same rat strain but administering 3 mg OTA/kg b.w. in the diet for 15 days, Abdel-
Wahhab et al. (2005) considered that OTA significantly reduced SOD activity. Meki and Hussein 
(2001) also found a reduction of GSH levels and SOD and GST activities in OTA treated Sprague-
Dawley rats (0.25 mg OTA/kg b.w. in NaHCO3 by oral gavage for 4 weeks) compared to 
controls. It should be noted that, when comparing all these different studies (in accordance or 
discordance to ours), not only the differences expected from different in vivo experimental 
designs or rat strains should be taken into account. Indeed, the major factors explaining 
contradictory results might be related with tissue preparation (freezing or not before 
homogenization), extract preparation (different speed and time of centrifugation or extraction 
buffers may lead to different cytosolic extracts), the amount of tissue or protein loaded, and 
the methods and calculations used for the different determinations. Indeed, these technical 
differences make comparisons among studies almost impossible. On the other hand, 
interpretation of results is generally based on statistical significance, without taking into 
account if the differences obtained are within the normal physiological variability of these 
enzymes or the protein levels in the rat tissue, which unfortunately has not been studied. For 
example, Ozçelik et al. (2004) reported a decrease in SOD activity in OTA-treated Wistar rats 
(289 µg OTA /kg b.w. in drinking water for 4 weeks) versus control animals. However, even that 
the differences were statistically significant (0.94 ± 0.14 vs. 0.78 ± 0.13 U/mg protein), both 
results might be within the normal physiological variability for SOD activity. Similarly, in the 
study from Bertelli et al. (2005), in which similar kits to the ones used in the present study for 
tGSH levels and SOD activity determination were used, the authors concluded that both the 
GSH/GSSG ratio and SOD activity were reduced by OTA treatment in Wistar rats (289 µg 
OTA/kg b.w. by oral gavage for 14 days). However, the mean values for SOD activity were 41 
and 51 U/mg of protein for the OTA-treated and control groups, respectively. Taking into 
account that the standard deviation for this study was around 10, it seems very likely that both 
results are within the normal physiological ranges.   
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A similar situation can be found when comparing DNA SBs or oxidised bases detected with the 
comet assay.  In accordance with the rest of the oxidative stress-related parameters measured, 
no differences due to OTA treatment or sex could be observed in our study. In agreement with 
our results and under similar experimental in vivo exposure conditions, Kamp et al. (2005) and 
Qi et al. (2014) did not find a significant increase on the DNA detected with the standard 
alkaline comet assay in kidney tissue of F344 rats. However, Kamp et al. (2005) concluded that 
OTA mediated-oxidative stress was detected when the enzyme Fpg was used in combination 
with the comet assay. Having a close look to the published data, the oxidised bases detected 
increased from 0.7% (approx.) in the control group to 3% (approx.) in the highest dose group 
(very low values even for tissues from non-treated animals); the statistically significant 
difference must be carefully interpreted in this case. Moreover, there was not a dose-
dependent relationship. The same interpretation would apply for the increased DNA SBs and 
oxidised bases observed in Domijan et al. (2006), in which kidneys from Wistar rats orally 
administered with 5 ng/kg, 0.05 and 5 mg/kg for 15 days were used. In this study, though the 
DNA SBs and oxidised base levels were very low in all groups (i.e., DNA SBs increased from 
0.4% tail DNA in the vehicle-treated group to 5.6% in the highest-dose group, while oxidised 
bases increased from 0.7 to 7.2 % tail DNA), they found a dose-response relationship. Kuroda 
et al. (2014) performed the comet assay in renal outer medulla of gpt delta rats treated with 0, 
70, 210 and 630 µg/kg OTA by oral gavage for 4 weeks. They also found a small but significant 
increase in the level of DNA SBs in treated animal (i.e., from 4% DNA in tail in control group to 
about 10-12% in treated animals); however, the increase was not dose dependent. Aydin et al. 
(2013) found a significant increase of DNA SBs in Sprague-Dawley rats treated p.o. with 0.5 mg 
OTA/kg b.w. for 14-15 days (i.e., from about 11% DNA in tail in control group to about 21% in 
treated animals).  
In another study with a similar experimental design than ours (Mally et al., 2005), the author 
concluded that a small but significant increase in DNA breakage was observed in the kidney, 
while when using Fpg, a significant increase over control was only evident in the high-dose 
(2000 µg OTA/kg b.w.) group. Unfortunately, the authors reported the results as tail moment, 
a measure that hinders the interpretation of the basal DNA damage in control animals, a good 
indicator of quality performance in the comet assay. Indeed, by comparing the comet images 
shown in their study and the given tail moment values, negative control animals seem to show 
very high % tail DNA (about 50%) when using Fpg.  Moreover, it is not clear if DNA SBs were 
substracted in the calculations in order to get net Fpg-sensitive sites (i.e., oxidised bases level). 
All these issues, together with the fact that the comparable dose to our study (500 µg OTA/kg 
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b.w.) was not reported in the results of the comet assay in presence of Fpg, make it impossible 
to correctly compare the results with the present study.  Similarly, in Želježić et al. (2006), DNA 
damage is expressed by a formula (DNA damage potency) that makes difficult the comparison 
with other studies and to really know the basal DNA damage of control animals.  
Overall, studies measuring oxidative stress related parameters after OTA treatment in vivo 
show controversial results. The main differences, apart from differences in the experimental 
design, might be due to i) different technical protocols and performance, ii) differences in 
calculations and reporting of results (formulas, etc) and iii) differences in the interpretation of 
the results (statistical differences vs. physiologically relevant differences).  
Moreover, even if OTA has produced positive responses in oxidative stress related parameters 
in many in vitro studies, the situation is not so crystal clear in vivo. As already discussed by 
Gautier et al. (2001), the discrepancy between the generation of ROS in vitro and in vivo and 
the resultant oxidative damage may be explained by the protective action of the antioxidant 
defences present in the animal model. Indeed, this was further supported in gene expression 
studies where great differences were found between an in vitro (Arbillaga et al., 2007a) and an 
in vivo analysis (Arbillaga et al., 2008). Many of the pathways (mitochondrial electron transport 
chain, DNA damage response, MAPK signalling, Wnt signalling, RNA transcription, etc.) 
affected in vitro, were not affected in vivo, and the oxidative stress response that was mainly 
up-regulated in vitro, was down-regulated in vivo. 
In conclusion, for the first time, different parameters related to oxidative stress have been 
measured following exactly the same methodological approach for both male and female F344 
rats after 7 and 21 days OTA administration with doses known to produce tumours in 2-years 
bioassays. In accordance with the similar OTA levels and histopathological changes observed in 
the same animals (Pastor et al., 2018) and with other oxidative-stress related parameters 
measured in both sexes (Hibi et al., 2011), our results support that there are no differences 
between males and females in the oxidative stress response to OTA. 
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1. Comet assay technical improvements 
A wide variety of both endogenous and exogenous (i.e., genotoxic) agents induce DNA damage 
in different ways, thereby providing the basis for mutations, which are strongly linked to 
cancer and other non-malignant diseases. As all mutagenic compounds are genotoxic, 
information on genotoxicity is of a key importance in the risk assessment process for different 
product classes to which humans may be exposed. In the food safety area, EFSA provided a 
Scientific opinion on genotoxicity testing strategies applicable to food and feed safety 
assessment (EFSA, 2011). In this document, an in vitro and in vivo step-wise approach was 
proposed for the generation and evaluation of data on genotoxic potential. In the suggested 
strategy, the test methods were referred (when available) by the corresponding harmonised 
guideline provided by the OECD. Although the OECD Guideline for the in vivo comet assay 
(OECD, 2016) was not developed at that time, the assay was considered for the in vivo follow-
up of positive genotoxic findings in vitro. 
The alkaline comet assay, first described as we use it nowadays in 1988 (Singh et al., 1988), is a 
useful tool in several areas of research. Among other advantages, its relative simplicity and the 
possibility to apply it to any cell type (as long as a cell suspension can be obtained), together 
with a high sensitivity for detecting low levels of DNA damage, made it become so popular. 
However, beginnings were never easy. The high-variability due to protocol differences 
between laboratories made it necessary to identify and study those important factors affecting 
the results. Final agarose concentration in gels (Azqueta et al., 2011; Ersson and Möller, 2011), 
duration of the alkaline unwinding treatment (Azqueta et al., 2011; Ersson and Möller, 2011; 
Yendle et al., 1997), electrophoresis conditions (Azqueta et al., 2011; Ersson and Möller, 2011; 
Speit et al., 1999; Vijayalaxmi et al., 1992), enzyme-incubation time (Ersson and Möller, 2011), 
and DNA staining (Olive et al., 1990) have been described as critical points influencing the 
outcome of the in vitro as well as the in vivo comet assays. On the other hand, although lysis 
conditions are also considered a critical variable (OECD, 2016), the influence of this parameter 
in the comet assay results has not been thoroughly studied. Several comet assay protocols 
recommended to lyse cells for at least 1 hour, being this time the most widely applied 
(Azqueta and Collins, 2013; Collins et al., 2008; Tice et al., 2000). However, 24-h and overnight 
lysis are also quite used (Azqueta and Collins, 2013).  
With the purpose of assessing the influence of lysis conditions in the comet assay results, we 
evaluated (in vitro) the effect of modifying the time of lysis in untreated and MMS-, H2O2- or X-
ray-treated cells on the alkaline comet assay results, as well as in untreated and Ro 19-8022 
Chapter 7 
126 
 
plus light-treated cells on the Fpg-modified comet assay results. In all the cases in which the 
standard comet assay was applied (i.e., without enzymes), similar results were obtained either 
skipping the lysis step or after 1 h of lysis. In the case of the Fpg-modified comet assay, a 5-min 
lysis was necessary to allow Fpg to reach the nucleus. As previously reported in ɣ-irradiated 
lymphocytes, the lysis step could be even omitted when the standard comet assay was applied 
(Vivek Kumar et al., 2009), as the alkaline treatment (a step forward in the comet assay 
protocol) is perfectly able to lyse the cells. However, except for X-ray-treated cells, our results 
showed an important increase in sensitivity for detecting DNA damage with longer times of 
lysis (i.e., more than 1 h), without an increased DNA damage in untreated cells (Chapters 3 and 
4). This observation might be due to the presence of some DNA lesions that could be 
spontaneously converted into AP-sites (i.e., ALS) during the lysis period, and so detected as SBs 
with the alkaline comet assay (ALS are converted into breaks during the alkaline treatment).  
In addition, we also checked the results obtained using two different lysis solutions; being one 
of them the most commonly used, and the other one prepared by adding N-Lauroylsarcosine 
sodium and DMSO (also very used). Similar results were obtained with both of them for every 
X-ray dose and time of lysis (Chapter 4). 
Overall, the duration of the lysis step should be tightly controlled when performing both the in 
vitro and in vivo comet assays. A constant time of lysis should we used to reduce the inter-
experimental and inter-laboratory variation, though using different times of lysis might be 
useful to increase the sensitivity and to ensure the detection of the DNA lesions induced by an 
unknown compound. Moreover, although more studies are needed to understand the 
underlying mechanism of the effect of the lysis time on the detection of different DNA lesions, 
varying the time of lysis could be used in the future to study the nature of induced DNA 
lesions.   
Regarding the in vivo comet assay, an In vivo Mammalian Alkaline Comet Assay OECD 
Guideline (OECD, 2016) was finally achieved as a result of the first formal validation trial (Uno 
et al., 2015a, 2015b). However, there are currently some specific limitations for this version of 
the assay; one of them has to do with the use of frozen tissues. It is often difficult from a 
logistical point of view to perform the in vivo comet assay in freshly-prepared tissues due to 
the high number of samples generated in a study. Thereby, freezing them for later analysis 
emerged as an alternative to solve this kind of difficulties when integrating the comet assay 
into repeated-dose toxicity studies (Recio et al., 2012; Rothfuss et al., 2011), or when 
combining it with the micronucleus assay (Recio et al., 2010). Although the OECD guideline 
recognises that, in the literature, tissues or cell nuclei have been successfully frozen for later 
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comet assay analysis, it also requires the demonstration of the laboratory’s proficiency in 
freezing methodologies (OECD, 2016). Moreover, currently there is no agreement on the best 
way to freeze and thaw tissues.  
The comet assay has been applied to several frozen rodent tissue samples such as liver (e.g., 
Folkmann et al., 2007; Jackson et al., 2013; Knudsen et al., 2015; Løhr et al., 2015; Risom et al., 
2007), kidney (e.g., Knudsen et al., 2015), lung (e.g., Folkmann et al., 2007; Jackson et al., 
2013; Knudsen et al., 2015; Risom et al., 2007), brain (e.g., Forsberg et al., 2015; Knudsen et 
al., 2015) and spleen (e.g., Knudsen et al., 2015). Moreover, many of these studies performed 
the comet assay in combination with enzymes (i.e., Fpg, Endo III or OGG1). Nevertheless, 
according to our knowledge, there is only one study demonstrating that similar results are 
obtained after performing the standard comet assay either in fresh or in frozen (liver and lung) 
tissues (Jackson et al., 2013).  
In the present work, different approaches (freezing/thawing combinations) were tested in liver 
tissues from untreated animals. Acceptable low % tail DNA values were obtained when small 
pieces inside a cryotube were flash frozen in liquid nitrogen, stored at -80°C and processed in a 
cold environment to prevent them to thaw until a cell suspension was obtained. Using the 
same approach, comparable results were obtained in fresh and 1-week or 1-month frozen 
liver, kidney and lung tissue samples from untreated or MMS-treated Wistar rats, with both 
the standard and the Fpg-modified comet assay (Chapter 5). Moreover, the group mean % tail 
DNA was lower than 6% for liver tissues of untreated animals in all cases (i.e., fresh, 1-week 
and 1-month frozen tissues), as recommended by the OECD Guideline for liver tissues of 
vehicle-treated animals (it does not provide recommendation for other tissues) (OECD, 2016). 
The Fpg-modified comet assay is very used in genotoxicity testing, although it is not covered in 
the OECD Guideline, as necessary protocol modifications still need to be adequately 
characterised (OECD, 2016). Results showed that the thawing process seems to be crucial in 
preserving DNA integrity, and that up to 1-month-frozen liver, kidney and lung tissues can be 
used in genotoxicity testing. A stability study of frozen samples is currently ongoing at the 
Laboratory of Toxicology, and frozen samples from the same organs will be analysed after 3-, 
6-months and 1-year storage at -80°C. 
The inclusion of assay controls in each comet assay run, an approach to detect experiments 
with abnormal results due to technical issues, to assess inter-experimental variation and 
correct it, allowed to discard one of the experiments. These controls will be used to normalise 
the results after the completion of the stability study.   
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2. Application of the in vivo alkaline comet assay to the evaluation of 
the oxidative stress-response after OTA-treatment in F344 rats 
The technical improvements for the in vivo comet assay enabled the application of the SOP to 
frozen kidney samples of a previous repeated-dose toxicity study of a naturally occurring food 
and feed contaminant (EFSA, 2006; WHO, 2008). OTA is a mycotoxin considered as one of the 
most powerful renal carcinogens in rodents and classified as a possible human carcinogen 
(group 2B) by the International Agency for Research on Cancer (IARC) (IARC, 1993). 
Unfortunately, its mechanism of action is still unknown and several hypotheses have been 
postulated regarding this issue (WHO, 2008), being indirect DNA reactivity mediated by 
oxidative stress one of them. Moreover, large sex-differences have been observed in different 
carcinogenicity studies, being male rats more sensitive than females (Boorman et al., 1992; 
Castegnaro et al., 1998; NTP, 1989; Son et al., 2003).  
With this scenario, and using the samples obtained in a previous repeated-dose toxicity study 
with male and female F344 rats treated with 0 or 0.5 mg OTA/kg b.w. for 7 days, or with 0, 
0.21 or 0.5 mg OTA/kg b.w. for 21 days, we applied both the standard alkaline and the Fpg-
modified comet assay to frozen kidney samples of those animals to look for oxidative DNA 
damage. In addition, we also checked several oxidative-stress related parameters in kidney 
tissue of the same animals, mainly GST activity, tGSH and GSSG levels and SOD activity. No 
biologically-relevant differences due to OTA treatment or sex differences in the response to 
OTA treatment were found neither with the comet assay, nor with the different oxidative 
stress-related parameters. 
3. Elaboration of Standard Operating Procedures (SOPs) 
The Laboratory of Toxicology of The Department of Pharmacology and Toxicology of the 
University of Navarra is also part of the Drug Development Unit (DDUNAV) of the University. 
DDUNAV covers the different phases of drug development from preclinical to clinical phases (I, 
II, III and IV) for the purpose of offering the scientific knowledge of the University to 
companies, but in compliance with regulatory requirements. More specifically, the Laboratory 
of Toxicology offers technical development of new testing methods and diverse services 
related to preclinical toxicity testing, both in vitro and in vivo. The Unit offers it services to 
pharma, cosmetic, agro-food and emerging biotechnological companies, as toxicological 
studies can be carried out according to regulatory guidelines and Good Laboratory Practices 
(GLPs). In addition to regulatory compliant versions, versatile toxicity assays to be applied in 
basic research or at early stages of drug development are also offered.  
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The Laboratory of Toxicology is based in a center that has a Quality Assurance Unit and has a 
Certificate of Compliance with GLPs issued by the regional Government of Navarra in 1996, 
which was recently renovated (2016). Thereby, the Laboratory of Toxicology develops 
Standard Operating Procedures (SOPs) in order to apply them to studies under GLP conditions 
requested by external promoters.  
In the present work, the knowledge derived from objective 1 (Chapters 3 and 4), regarding the 
time of lysis, was applied to the SOP for the in vitro alkaline comet assay. Therefore, a constant 
time of lysis within a set of experiments is recommended in that document. Furthermore, the 
SOP has been already approved by the Quality Assurance Unit, and thus the in vitro comet 
assay is currently offered as an external service for studies performed under GLPs. 
On the other hand, the expertise gained in the application of the in vivo comet assay to both 
fresh and frozen tissue samples (Chapter 5) led to the elaboration of a SOP for the in vivo 
comet assay, which is currently being revised by the Quality Assurance Unit and will also be 
available soon.  
Because of the public character of the present work, the aforementioned SOPs are not 
included due to confidentiality reasons. 
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Conclusions 
1. With regard to lysis conditions: 
1.1. In the standard alkaline comet assay, the lysis step is not necessary to obtain the 
nucleoids since the alkaline treatment step is able not only to denature DNA but also 
to lyse the cells. In the case of the Fpg-modified comet assay, 5 min of lysis is enough 
to allow the Fpg to reach the nucleus. 
1.2. Increasing the time of lysis from 1 hour to 1 week highly increases the sensitivity of 
the assay depending on the DNA lesion detected.  
1.3. A constant time of lysis should be used in order to compare results from different 
experiments or laboratories. 
1.4. Adding N-Lauroylsarcosine sodium and DMSO to the commonly used lysis solution 
does not affect the standard comet assay outcome.  
1.5. Varying the time of lysis could be used in the future to study the nature of the DNA 
lesions induced; however, more studies are needed to understand the mechanism by 
which extra breaks are detected after applying long lysis periods.  
2. With regard to tissue freezing/thawing methods: 
2.1. Acceptable low % tail DNA values, regarding both DNA SBs (plus ALS) and Fpg-
sensitive sites, were obtained in frozen liver tissue from untreated animals when flash 
frozen as small pieces in liquid nitrogen, stored at -80°C and processed in a cold 
environment preventing the tissue samples to thaw until a cell suspension was 
obtained. This thawing process is of a key importance to avoid causing unintentional 
DNA damage. 
2.2. Frozen (for up to one month) liver, kidney and lung tissue samples, can be used in the 
in vivo comet assay (both with and without Fpg) for genotoxicity testing. 
2.3. The inclusion of assay controls in each comet assay run allows to detect technical 
problems and assess inter-experimental variability.  
3. With regard to the application of the in vivo comet assay to kidney frozen samples from a 
previous OTA repeated-dose study:  
3.1. The new SOP developed for the comet assay was successfully applied, both with and 
without Fpg, to frozen kidney tissue samples obtained in a OTA repeated-dose toxicity 
study.  
3.2. No sex-differences, nor an increase in SBs or in Fpg-sensitive sites was found in kidney 
tissue samples of male and female OTA-treated F344 rats; this correlated to the 
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unaltered kidney oxidative-stress related parameters SOD and GST activities, and 
tGSH and GSSG levels, measured in the same samples. 
4. With regard to the development of SOPs to be later applied in genotoxicity studies under 
GLP conditions: 
4.1. The use of a constant time of lysis within a set of comet assay experiments was 
included in the SOP for the in vitro comet assay. 
4.2. A SOP for the in vivo comet assay, both with and without Fpg, to be applied in fresh or 
frozen tissues, was developed.  
 
